Conjoint Professor Jim Denham

Conjoint Professor Jim Denham

Conjoint Professor

School of Medicine and Public Health

Career Summary

Biography

Professor Denham’s main research field is clinical oncology, in particular the design and conduct of multi-centre clinical trials involving the use of radiotherapy. He also has major interests in radiation injury to healthy normal tissue and in improving the delivery of radiotherapy.

He completed his training at the Middlesex Hospital and Mount Vernon Hospital rotation between 1978 and 1983. During this time he received his Fellowship in Radiotherapy and Oncology with the Royal College of Radiologists (UK) in 1980 and was awarded the London University MD diploma in 1983 after a successful research project by thesis addressing the natural history of the Follicular Non-Hodgkin’s Lymphomas. After immigrating to Australia in 1983 to become a Staff Specialist in Radiation Oncology at the Royal Adelaide Hospital, he commenced his clinical research career with pilot studies of chemo-radiation in the pre-operative and definitive treatment of oesophageal cancer. He received his Fellowship of the Royal Australian College of Radiologists in 1986. 

He was appointed Senior Staff Specialist and Director of Radiation Oncology in the new department at the Mater Hospital (Newcastle) in 1987 and was awarded his Conjoint Professorship title by the University of Newcastle in 1992. During the early years of his employment in Newcastle Denham played a major role in establishing Australia and New Zealand’s (ANZ) multicentre trials group that addresses the role of radiotherapy alone or in combination with other modalities. This group is called the Trans-Tasman Radiation Oncology Group (TROG). Denham was a founding member of TROG in 1986 and after chairing the fledgling group he became its first President during the years 1994-2000 and oversaw its growth phase. In 2014 it celebrated its 25th anniversary and had reasonable cause for satisfaction. During its first 25 years TROG conducted 21 Phase 2 trials and 26 randomised controlled Phase 3 trials (which include 9 trials involving international collaboration) which has involved the participation of 12,000 subjects from 28 Australian and New Zealand cancer centres. It has also conducted more than 20 treatment delivery studies and non-trial related clinical studies.

He has also played a major role in the design and direction of ANZ’s two largest cancer trials. These were successive trials for men with locally advanced prostate cancer. The TROG 96.01 trial enrolled 818 subjects between 1996 and 2000 and reported its findings in 23 publications between 2000 and 2013 which included its 5 and 10 years endpoint outcomes. The TROG 03.04 (RADAR) trial enrolled 1071 subjects between 2003 and 2006 and to date has reported its findings in 25 publications between 2008 and 2015, including its 6.5 year endpoint outcomes. Both trials demonstrated that statistically significant improvements in cancer related outcomes could be achieved without clinically important increases in treatment related morbidity.

New South Wales Cancer Registry data in 2005 indicated that the Hunter had the highest mortality rates in the State for four major cancers. This stimulated Denham to become a public advocate for earlier cancer diagnosis and treatment. Together with predominantly Hunter based non-medical community figures, groups and charities he therefore worked to improve awareness of prostate cancer and promote its earlier diagnosis and more effective treatment. As a direct result a public advertising campaign which partly targeted the womenfolk of the Hunter was launched in 2006. Over the next 18 months this campaign succeeded in lifting the Hunter's prostate cancer detection rate from the lowest in NSW to the highest!  In 2013 Denham was recognised for these and other community based efforts with a NSW Government Community Service Award.

Research Expertise

Professional Interests & Research 

At the Newcastle Mater Hospital Denham's research interests have considerably progressed in the areas of translational clinical radiobiology and normal tissue radiation injury, improvements in radiation treatment delivery, multi-centre collaborative clinical research, and more latterly, in clinical pycho-oncological issues.

Translational clinical radiobiology and normal tissue radiation injury initiatives have focussed on the quantification of normal tissue effects that result from the use of different fractionation regimes. An ambitious three year NHMRC supported project that sought to define isoeffective permutations of total dose and dose rate in the ‘low’ to ‘medium’ dose rate range for the acutely reacting human mucosa and skin was the first of these. Measurements derived using a newly-developed reflectance spectrophotometer have been an important aspect of this project and have led to the use of this equipment in parallel projects that formed the basis of Conjoint Assoc Prof Chris Hamilton’s MD thesis. Other clinical colleagues, Assoc Prof Peter O'Brien and Dr Chris Wratten, have designed projects which addressed the effects of radiation on the rectal mucosa and the problem of breast oedema and fatigue in patients treated conservatively for breast cancer. More recent work has focussed on the role of inflammatory and reparative processes involved in normal tissue reactions. Aspects of this work have been carried out in collaboration with Prof Martin Hauer-Jensen in Little Rock, Arkansas, Prof Wolfgang Dörr in Dresden, Germany and Dr Paivi Simonen in Finland.

The strong Physics group that developed at Newcastle under the leadership of Professors Tomas Kron and Martin Ebert, now has a lengthy track record in all areas of in vivo dosimetry, including the design and evaluation of novel methodologies for assessing skin dose and doses at interfaces. In addition to in vivo studies, the group has defined explicit dose distributions in a range of human phantom situations for both photons and electrons and has run two inter-centre dosimetry studies. Two masters and two PhD projects have come directly from these efforts. More recently Conjoint Prof Peter Greer has led the Physics team’s strong research efforts. A plethora of technological advances in recent years has led to the promise of major improvements in the accuracy of treatment delivery and, as a result, improvement in treatment outcome. At the Calvary Mater Hospital major improvements in treatment delivery have come from the successful implementation of electronic portal imaging beam direction verification and image guided radiotherapy using MRI fusion planning with implanted gold grain fiducial markers and intensity modulated radiotherapy. Funding support for some of these projects has come from the NHMRC and other agencies.

Multi-centre Collaborative Clinical Research commenced  in 1989 when the Newcastle Mater Radiation Oncology Department took pride in becoming an inaugural member of the Trans Tasman Radiation Oncology Group (TROG), a multi-centre group committed to pursuing advances in radiation therapy through the conduct of clinical trials. It has been particularly satisfying to see TROG go such a long way towards achieving its initial goal of promoting inter-centre collaboration so quickly. TROG now includes over 200 members from 35 centres in Australia and New Zealand. Denham has had the privilege of chairing TROG’s 89.04, 96.02, 96.03 and 98.04 radio-chemotherapy oesophageal cancer protocols and the 96.01 randomised androgen deprivation prostate cancer trial. Presently he is the Director of TROG’s 03.04 (RADAR) prostate cancer trial. Overseas collaborations with Prof Anthony D'Amico at the Dana Farber Cancer Institute, Boston and Prof David Dearnaley at the Royal Marsden Hospital, Surrey have been important developments. In 2006 Denham's research interests extended to the field of Psycho-Oncology and have profited much from collaborations with the former Professor of Nursing at Newcastle Irena Madjar, and Professors Chris Sharpley and Vicki Bitsika of the University of New England.

Overall Denham's publications include more than190 full length articles, 17 letters and 5 book chapters. His lifetime research funding amounts to $10.3M from national competitive sources (including 12 NHMRC projects grants), $7.7M from industrial sources and $1.3M from institutional sources. Relative to opportunity Denham’s contribution may be viewed in a favourable light because he remains to this day a full time Senior Staff Specialist with a heavy clinical workload. His research activities were recognised locally in 2006 with the HMRI Sparke-Helmore Award for Research Excellence, and in Europe in 2007 with Honorary membership of the European Society for Radiotherapy & Oncology (ESTRO). In 2013 the University of New England awarded him the title of Honorary Professor .

Denham was recognised in the 2016 Australia Day's Honours list with a Medal of the Order of Australia (OAM) for services to Medicine and Medical Research in particular. 


Teaching Expertise

This has included the training of registrars for Part I and II FRCR and FRACR, FRACS and FRACOG, the teaching of medical students from the Universities of Leeds, London, Adelaide and Newcastle, and formal lectures to radiographers and nurses in training at The Middlesex, Mount Vernon, Royal Adelaide and Newcastle Calvary Mater Hospitals. In 1986 Denham directed the production of two videos produced by Adelaide University, to describe the operation of the Radiotherapy Department for students and patients. Since then the use of video as an educational tool in medicine has since become an interest of the Department in Newcastle. Information videos for patients and their families introducing them to the process of external beam radiotherapy and gynaecological intracavitary treatment have been produced in collaboration with the Newcastle Medical Communications Unit. More technical versions for medical students and graduates have also been produced. In early 1988 the Radiation Oncology Department at the Calvary Mater Newcastle Hospital was accredited by the Royal Australian and New Zealand College of Radiologists to train registrars for specialist careers in radiation oncology. Denham successfully lobbied Hunter parliamentarians to establish of new course in Therapeutic Radiography at Newcastle University in 1990. This turned out to be a very significant development. The long-term viability of radiotherapy services in the Hunter region would have been doubtful, at best, had this development not occurred. As Conjoint Professor at Newcastle University Medical School, Denham chaired the multidisciplinary Oncology Undergraduate Committee from 1992 to 1995. During these years the Committee made a number of important revisions to the course. Further to the Committee's recommendations, the Medical School formulated a policy concerning curriculum content, and a map of Oncology related input into the curriculum was generated. Cancer topic related teaching now has the status of a formal strand in the curriculum structure. An additional task during this period was the preparation and marking of questions for the students' final assessment prior to graduation. In 1998, Denham became Coordinator of the Bachelor of Medical Sciences program, which provides 3rd year medical students with training in research methodology through involvement in Faculty research programs. He ran the medical lecture program for the Year 2 and 3 Medical Radiation Science Radiation Therapy undergraduates between 2004 and 2007. 

Administrative Expertise

The Calvary Mater Newcastle Hospital houses a modern well equipped Radiation Oncology Department. Denham's task as Director of the Department from 1987 to 1992 was to oversee its development from a small unit to a well-equipped moderately sized modern department that provides a comprehensive regional service, works in close liaison with other disciplines, and is accredited for postgraduate training. Implicit in this process were the development of a sound administrative structure and the instigation of a comprehensive quality assurance program that covers all aspects of departmental operation. By 1992 the Department housed two dual modality high energy linear accelerators, a single modality 4MV linear accelerator, a superficial treatment unit, simulator, interactive CT computer planning hardware, full mould room facilities including a tissue compensation filter cutter, and remote afterloading gynaecological and interstitial units. The Department is now the largest in NSW with 5 linear accelerators, a superficial x-ray unit, a high dose rate gynaecological brachytherapy unit and two CT simulators. As Conjoint Professor from 1992 Denham’s task was to promote the academic development of the Department. A large number of research and developmental projects have commenced and several are now complete. Those efforts are reflected in publications, grants and staff development. Since August 1987 members of the Department have published over 300 papers in Australasian and international journals and presented more than 150 papers at Australasian and international meetings. Prizes for best scientific contributions to the annual meetings of the respective professional bodies and organisations have been won by the registrar staff (RACR, 1989 and 1991 Varian prizes), by the radiography students (AIR, 1991 Harrold Anderson prize), by the Physics staff (Varian prize 1993) and by the senior medical staff (ESTRO 1992 and 1994, RACR 1996 Medical Applications prize). Two Masters, three PhD and two MD projects have now been completed or are now in the process of completion by various Departmental staff. 

Publications highlights (10 most significant publications)

  1. Peng Y, Dear KBG, Denham JW. A generalized F mixture model for cure rate estimation. Statistics in Medicine 1998;17: 813-830
  2. Denham J, Peters L, Johansen J, Poulsen M, Lamb D, Hindley A, O'Brien P, Spry N, Penniment M, Krawitz H, Williamson S, Bear J, Tripcony, L. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? RadiotherOncol 1999; 52: 157-164
  3. Poulsen MG, Denham JW, Peters LJ, Lamb DS, Spry NA, Hindley A, Krawitz H, Hamilton C, Keller J, Tripcony L, Walker Q. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group Study (TROG 91.01) RadiotherOncol 2001; 60: 113-122
  4. Denham JW, Hauer-Jensen M. The radiotherapeutic injury - a complex 'wound'. RadiotherOncol 2002; 63: 129-145
  5. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley D, Joseph D, Millar J, North J, Walpole ET, Denham JW. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6: 659-668
  6. Christie DRH, Denham JW, Steigler A, Lamb DS, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, Francis L, Kramar A, D'Este C, Bill D. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation  RadiotherOncol 2005;77(2): 117-125
  7. Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Gleeson PS, Greer PB, D'Este C on behalf of the Trans-Tasman Radiation Oncology Group Trialists. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.Lancet Oncol 2008;9:1058-1068
  8. Capp A, Inostroza-Ponta M, Bill D, Moscato P, Lai C, Christie D, Lamb D, Turner S, Joseph D, Matthews J, Atkinson C, North N, Michael M, Spry NA, Tai KH, Wynne C, Duschesne G, Steigler A, Denham JW.  Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. RadiotherOncol 2008;90(3): 400-407
  9. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.Lancet Oncol 2011;12(5): 451-459
  10. Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.Lancet Oncol  2012; 13(12): 1260-127[Main oncologic endpoints of the TROG 03.04 (RADAR) randomised phase 3 trial for men with locally advanced prostate cancer (see below under "Other Comments")]

 

Qualifications

  • Doctor of Medicine, University of London
  • Bachelor of Medicine & Surgery, University of London

Keywords

  • Androgen suppression and prostate cancer
  • Clinical Trials
  • Normal tissue effects of radiotherapy
  • Prostate Cancer
  • Radiotherapy and prostate cancer
  • Radiotherapy treatment delivery

Fields of Research

Code Description Percentage
029999 Physical Sciences not elsewhere classified 40
111299 Oncology and Carcinogenesis not elsewhere classified 60

Professional Experience

Academic appointment

Dates Title Organisation / Department
13/12/2013 -  Honorary Professor University of New England
Australia
1/01/2009 -  Membership - Special Advisory Board of The Lancet Oncology Special Advisory Board of The Lancet Oncology
Australia
1/01/1996 -  Editorial Board - Journal of the European Society for Therapeutic Radiation and Oncology (Radiotherapy & Oncology) Journal of the European Society for Therapeutic Radiation and Oncology (Radiotherapy & Oncology)
Australia
1/08/1992 -  Conjoint Professor Radiation Oncology The University of Newcastle
Australia
1/08/1987 - 1/09/1992 Director Newcastle Mater Misericordiae Hospital
Department of Radiation Oncology
Australia
1/10/1983 - 1/07/1987 Senior Staff Specialist The Royal Adelaide and Queen Elizabeth Hospitals
Department of Radiation Oncology
Australia
1/10/1983 - 1/07/1987 Clinical Senior Lecturer The University of Adelaide
Australia
1/07/1980 - 1/09/1983 Honorary Lecturer University of London

Professional appointment

Dates Title Organisation / Department
1/10/1992 -  Senior Staff Specialist Calvary Mater Newcastle
Department of Radiation Oncology
1/07/1980 - 1/09/1983 Senior Registrar The Middlesex and Mount Vernon Hospitals
Radiotherapy and Oncology
United Kingdom
1/10/1979 - 1/06/1980 Acting Senior Registrar The Middlesex Hospital
Radiotherapy and Oncology
United Kingdom
1/09/1978 - 1/10/1979 Registrar The Middlesex and Mount Vernon Hospitals
Radiotherapy and Oncology
United Kingdom
1/09/1977 - 1/08/1978 Registrar Cookridge Hospital (Leeds)
Radiotherapy and Oncology
United Kingdom
1/09/1976 - 1/08/1977 Senior House Officer Cookridge Hospital (Leeds)
Radiotherapy and Oncology
United Kingdom
1/08/1974 - 1/08/1976 Assistant in General Practice Private Practice
Australia
1/01/1974 - 1/07/1974 House Physician Chelmsford and Essex Hospital
United Kingdom
1/07/1973 - 1/01/1974 House Surgeon Chelmsford and Essex Hospital
United Kingdom

Awards

Award

Year Award
2015 Order of Australia (OAM)
Australian Government

Recognition

Year Award
2013 2013 NSW Government Community Service Award
Government of NSW

Research Award

Year Award
2006 2006 HMRI Sparke-Helmore Award for Research Excellence
Hunter Medical Research Institute (HMRI)
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (4 outputs)

Year Citation Altmetrics Link
2009 Hauer-Jenson M, Denham J, Hovdenak N, Kumar KS, 'Mechanisms, diagnosis and treatment of radiation injuries in the small bowel and colon', Radiation Injury, Lippincott Williams & Wilkins, Philadelphia, PA (2009)
2003 Hauer-Jensen M, Denham JW, Wang J, 'Mechanisms and modification of the radiation response of gastrointestinal organs', -, Springer Verlag, Heidelberg, 49-72 (2003) [B1]
2002 Wratten C, Kilmurray J, Wright S, O'Brien P, Back M, Hamilton C, Denham J, 'A Study of High Frequency Ultrasound to Assess Cutaneous Oedema in Conservatively Managed Breast', Normal Tissue Reactions in Radiotherapy and Oncology, Frontiers of Radiation Therapy Oncology, Switzerland 121-127 (2002) [B1]
Citations Scopus - 2Web of Science - 2
1991 Denham J, 'Synchronous radiation and chemotherapy for locally advanced cancer: is it the answer?', Cancer: Changing Concepts in Management, Australasian Medical Publishing Co., Sydney (1991)
Show 1 more chapter

Journal article (209 outputs)

Year Citation Altmetrics Link
2015 Yahya N, Ebert MA, Bulsara M, House MJ, Kennedy A, Joseph DJ, Denham JW, 'Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models', Radiotherapy and Oncology, 117 277-282 (2015) [C1]

© 2015 Elsevier Ireland Ltd. Background and purpose This study aimed to compare urinary dose-symptom correlates after external beam radiotherapy of the prostate using commonly ut... [more]

© 2015 Elsevier Ireland Ltd. Background and purpose This study aimed to compare urinary dose-symptom correlates after external beam radiotherapy of the prostate using commonly utilised peak-symptom models to multiple-event and event-count models which account for repeated events. Materials and methods Urinary symptoms (dysuria, haematuria, incontinence and frequency) from 754 participants from TROG 03.04-RADAR trial were analysed. Relative (R1-R75 Gy) and absolute (A60-A75 Gy) bladder dose-surface area receiving more than a threshold dose and equivalent uniform dose using exponent a (range: aâ [1 ... 100]) were derived. The dose-symptom correlates were analysed using; peak-symptom (logistic), multiple-event (generalised estimating equation) and event-count (negative binomial regression) models. Results Stronger dose-symptom correlates were found for incontinence and frequency using multiple-event and/or event-count models. For dysuria and haematuria, similar or better relationships were found using peak-symptom models. Dysuria, haematuria and high grade (=2) incontinence were associated to high dose (R61-R71 Gy). Frequency and low grade (=1) incontinence were associated to low and intermediate dose-surface parameters (R13-R41 Gy). Frequency showed a parallel behaviour (a = 1) while dysuria, haematuria and incontinence showed a more serial behaviour (a = 4 to a = 100). Relative dose-surface showed stronger dose-symptom associations. Conclusions For certain endpoints, the multiple-event and event-count models provide stronger correlates over peak-symptom models. Accounting for multiple events may be advantageous for a more complete understanding of urinary dose-symptom relationships.

DOI 10.1016/j.radonc.2015.10.003
2015 Buffart LM, Newton RU, Chinapaw MJ, Taaffe DR, Spry NA, Denham JW, et al., 'The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer', Cancer, (2015) [C1]

BACKGROUND: The current study examined effects, moderators (for whom), and mediators (working mechanisms) of 12 months of exercise on health-related quality of life (HRQoL) in old... [more]

BACKGROUND: The current study examined effects, moderators (for whom), and mediators (working mechanisms) of 12 months of exercise on health-related quality of life (HRQoL) in older long-term survivors of prostate cancer. METHODS: In total, 100 men aged 71.7 years (standard deviation, 6.4 years) were randomly assigned to 6 months of supervised aerobic and resistance exercise followed by 6 months of a home-based exercise maintenance program (EX group) or printed education material regarding physical activity for 12 months (PA group). Assessments took place at baseline and after 6 and 12 months. Generalized estimating equations were used to study the effects of EX versus PA on HRQoL at 6 and 12 months, adjusting for baseline HRQoL. The authors examined potential sociodemographic and clinical moderators by adding interaction terms, and potential physical and psychological mediators using the product-of-coefficients test. RESULTS: At 6 months, significant beneficial effects were found for global QoL, physical function, and social function in the EX group compared with the PA group. For physical function, beneficial effects were sustained at 12 months. Moderation analyses demonstrated larger effects of EX versus PA for patients who were married, started exercising sooner after their diagnosis, and previously used bisphosphonates. Changes in lower body functional performance significantly mediated the effect of EX on global QoL, physical function, and social function. No mediating effects on HRQoL were found for aerobic fitness, physical activity, fatigue, distress, or falls self-efficacy. CONCLUSIONS: Aerobic and resistance exercise appears to have beneficial effects on HRQoL among older, long-term survivors of prostate cancer. Effects were moderated by marital status, time since diagnosis, and use of bisphosphonates, and were mediated by lower body functional performance.

DOI 10.1002/cncr.29406
Citations Web of Science - 1
2015 Ebert MA, Foo K, Haworth A, Gulliford SL, Kennedy A, Joseph DJ, Denham JW, 'Gastrointestinal dose-histogram effects in the context of dose-volume-constrained prostate radiation therapy: Analysis of data from the radar prostate radiation therapy trial', International Journal of Radiation Oncology Biology Physics, 91 595-603 (2015) [C1]

Copyright © 2015 Published by Elsevier Inc. All rights reserved. Purpose To use a high-quality multicenter trial dataset to determine dose-volume effects for gastrointestinal (GI... [more]

Copyright © 2015 Published by Elsevier Inc. All rights reserved. Purpose To use a high-quality multicenter trial dataset to determine dose-volume effects for gastrointestinal (GI) toxicity following radiation therapy for prostate carcinoma. Influential dose-volume histogram regions were to be determined as functions of dose, anatomical location, toxicity, and clinical endpoint. Methods and Materials Planning datasets for 754 participants in the TROG 03.04 RADAR trial were available, with Late Effects of Normal Tissues (LENT) Subjective, Objective, Management, and Analytic (SOMA) toxicity assessment to a median of 72 months. A rank sum method was used to define dose-volume cut-points as near-continuous functions of dose to 3 GI anatomical regions, together with a comprehensive assessment of significance. Univariate and multivariate ordinal regression was used to assess the importance of cut-points at each dose. Results Dose ranges providing significant cut-points tended to be consistent with those showing significant univariate regression odds-ratios (representing the probability of a unitary increase in toxicity grade per percent relative volume). Ranges of significant cut-points for rectal bleeding validated previously published results. Separation of the lower GI anatomy into complete anorectum, rectum, and anal canal showed the impact of mid-low doses to the anal canal on urgency and tenesmus, completeness of evacuation and stool frequency, and mid-high doses to the anorectum on bleeding and stool frequency. Derived multivariate models emphasized the importance of the high-dose region of the anorectum and rectum for rectal bleeding and mid- to low-dose regions for diarrhea and urgency and tenesmus, and low-to-mid doses to the anal canal for stool frequency, diarrhea, evacuation, and bleeding. Conclusions Results confirm anatomical dependence of specific GI toxicities. They provide an atlas summarizing dose-histogram effects and derived constraints as functions of anatomical region, dose, toxicity, and endpoint for informing future radiation therapy planning.

DOI 10.1016/j.ijrobp.2014.11.015
Citations Scopus - 2
2015 Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, et al., 'Registering prostate external beam radiotherapy with a boost from high-dose-rate brachytherapy: A comparative evaluation of deformable registration algorithms', Radiation Oncology, 10 (2015) [C1]

© 2015 Moulton et al. Background: Registering CTs for patients receiving external beam radiotherapy (EBRT) with a boost dose from high-dose-rate brachytherapy (HDR) can be challe... [more]

© 2015 Moulton et al. Background: Registering CTs for patients receiving external beam radiotherapy (EBRT) with a boost dose from high-dose-rate brachytherapy (HDR) can be challenging due to considerable image discrepancies (e.g. rectal fillings, HDR needles, HDR artefacts and HDR rectal packing materials). This study is the first to comparatively evaluate image processing and registration methods used to register the rectums in EBRT and HDR CTs of prostate cancer patients. The focus is on the rectum due to planned future analysis of rectal dose-volume response. Methods: For 64 patients, the EBRT CT was retrospectively registered to the HDR CT with rigid registration and non-rigid registration methods in VelocityAI. Image processing was undertaken on the HDR CT and the rigidly-registered EBRT CT to reduce the impact of discriminating features on alternative non-rigid registration methods applied in the software suite for Deformable Image Registration and Adaptive Radiotherapy Research (DIRART) using the Horn-Schunck optical flow and Demons algorithms. The propagated EBRT-rectum structures were compared with the HDR structure using the Dice similarity coefficient (DSC), Hausdorff distance (HD) and average surface distance (ASD). The image similarity was compared using mutual information (MI) and root mean squared error (MSE). The displacement vector field was assessed via the Jacobian determinant (JAC). The post-registration alignments of rectums for 21 patients were visually assessed. Results: The greatest improvement in the median DSC relative to the rigid registration result was 35 % for the Horn-Schunck algorithm with image processing. This algorithm also provided the best ASD results. The VelocityAI algorithms provided superior HD, MI, MSE and JAC results. The visual assessment indicated that the rigid plus deformable multi-pass method within VelocityAI resulted in the best rectum alignment. Conclusions: The DSC, ASD and HD improved significantly relative to the rigid registration result if image processing was applied prior to DIRART non-rigid registrations, whereas VelocityAI without image processing provided significant improvements. Reliance on a single rectum structure-correspondence metric would have been misleading as the metrics were inconsistent with one another and visual assessments. It was important to calculate metrics for a restricted region covering the organ of interest. Overall, VelocityAI generated the best registrations for the rectum according to the visual assessment, HD, MI, MSE and JAC results.

DOI 10.1186/s13014-015-0563-9
2015 Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, et al., 'Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial', Radiotherapy and Oncology, 115 301-307 (2015) [C1]
DOI 10.1016/j.radonc.2015.05.016
Citations Scopus - 5
Co-authors John Attia, Liz Holliday, Christopher Oldmeadow, Allison Steigler
2015 Ebert MA, Bulsara M, Haworth A, Kearvell R, Richardson S, Kennedy A, et al., 'Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: Are the results reflected in observed toxicity rates?', Journal of Medical Imaging and Radiation Oncology, 59 99-108 (2015) [C1]

© 2014 The Royal Australian and New Zealand College of Radiologists. Introduction Multicentre radiotherapy clinical trials can incorporate quality assurance (QA) procedures for e... [more]

© 2014 The Royal Australian and New Zealand College of Radiologists. Introduction Multicentre radiotherapy clinical trials can incorporate quality assurance (QA) procedures for ensuring consistent application of the trial protocol in the planning, delivery and reporting of participant treatments. Subsequently detected variations from trial protocol have previously been shown to reduce treatment efficacy, although little has been shown for toxicity rates. The purpose of this study was to investigate the association of QA measures and protocol variations on toxicity incidence in the context of a prostate radiotherapy trial. Methods Using QA records from the TROG 03.04 RADAR trial, the impact of variations on gastrointestinal (GI) and genito-urinary (GU) toxicities was investigated. Results Protocol variation rates were lower than reported in previous studies, and showed little correlation with GI toxicity outcomes. Variations classified as 'major' showed a non-significant trend for increased toxicity relative to those classified as 'minor'. Results from a Level III phantom-based dosimetry study showed some correlation with GI toxicity, whereas ranking on a set-up accuracy study did not impact on toxicity. Toxicity in general increased with the number of participants accrued per centre, at odds with previous reports relating to disease progression, with a potential link to increases in low-mid-range rectal doses in the cohort from higher-accruing centres. No QA-related variables correlated with GU toxicities. Conclusions Besides non-significant trends, minimal association was observed between QA variables and toxicity rates for the RADAR trial. The intention of the trial's QA programme was to reduce treatment variations and minimise toxicity in the context of a relevantly advanced treatment approach.

DOI 10.1111/1754-9485.12212
2015 Yahya N, Ebert MA, Bulsara M, Haworth A, Kennedy A, Joseph DJ, Denham JW, 'Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial', Radiotherapy and Oncology, 116 112-118 (2015) [C1]
DOI 10.1016/j.radonc.2015.06.011
Citations Scopus - 1
2015 Carter G, Clover K, Britton B, Mitchell AJ, White M, McLeod N, et al., 'Wellbeing during Active Surveillance for localised prostate cancer: A systematic review of psychological morbidity and quality of life', Cancer Treatment Reviews, 41 46-60 (2015) [C1]

© 2014 Elsevier Ltd. Background: Active Surveillance (AS) is recommended for the treatment of localised prostate cancer; however this option may be under-used, at least in part b... [more]

© 2014 Elsevier Ltd. Background: Active Surveillance (AS) is recommended for the treatment of localised prostate cancer; however this option may be under-used, at least in part because of expectations of psychological adverse events in those offered or accepting AS. Objective: (1) Determine the impact on psychological wellbeing when treated with AS (non-comparative studies). (2) Compare AS with active treatments for the impact on psychological wellbeing (comparative studies). Method: We used the PRISMA guidelines and searched Medline, PsychInfo, EMBASE, CINHAL, Web of Science, Cochrane Library and Scopus for articles published January 2000-2014. Eligible studies reported original quantitative data on any measures of psychological wellbeing. Results: We identified 34 eligible articles (. n=. 12,497 individuals); 24 observational, eight RCTs, and two other interventional studies. Studies came from North America (16), Europe (14) Australia (3) and North America/Europe (1). A minority (5/34) were rated as high quality. Most (26/34) used validated instruments, whilst a substantial minority (14/34) used watchful waiting or no active treatment rather than Active Surveillance. There was modest evidence of no adverse impact on psychological wellbeing associated with Active Surveillance; and no differences in psychological wellbeing compared to active treatments. Conclusion: Patients can be informed that Active Surveillance involves no greater threat to their psychological wellbeing as part of the informed consent process, and clinicians need not limit access to Active Surveillance based on an expectation of adverse impacts on psychological wellbeing.

DOI 10.1016/j.ctrv.2014.11.001
Citations Scopus - 1
Co-authors Gregory Carter
2015 Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, et al., 'Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.', Pathology, 47 520-525 (2015)
DOI 10.1097/PAT.0000000000000318
Citations Scopus - 1
Co-authors John Attia, Allison Steigler
2014 Yahya N, Ebert MA, Bulsara M, Haworth A, Kearvell R, Foo K, et al., 'Impact of treatment planning and delivery factors on gastrointestinal toxicity: An analysis of data from the RADAR prostate radiotherapy trial', Radiation Oncology, 9 (2014) [C1]

© Yahya et al. ; licensee BioMed Central Ltd. Background: To assess the impact of incremental modifications of treatment planning and delivery technique, as well as patient anato... [more]

© Yahya et al. ; licensee BioMed Central Ltd. Background: To assess the impact of incremental modifications of treatment planning and delivery technique, as well as patient anatomical factors, on late gastrointestinal toxicity using data from the TROG 03.04 RADAR prostate radiotherapy trial. Methods: The RADAR trial accrued 813 external beam radiotherapy participants during 2003-2008 from 23 centres. Following review and archive to a query-able database, digital treatment plans and data describing treatment technique for 754 patients were available for analysis. Treatment demographics, together with anatomical features, were assessed using uni- and multivariate regression models against late gastrointestinal toxicity at 18-, 36- and 54-month follow-up. Regression analyses were reviewed in the context of dose-volume data for the rectum and anal canal. Results: A multivariate analysis at 36-month follow-up shows that patients planned using a more rigorous dose calculation algorithm (DCA) was associated with a lower risk of stool frequency (OR: 0.435, CI: 0.242-0.783, corrected p = 0.04). Patients using laxative as a method of bowel preparation had higher risk of having increased stool frequency compared to patients with no dietary intervention (OR: 3.639, CI: 1.502-8.818, corrected p = 0.04). Despite higher risks of toxicities, the anorectum, anal canal and rectum dose-volume histograms (DVH) indicate patients using laxative had unremarkably different planned dose distributions. Patients planned with a more rigorous DCA had lower median DVH values between EQD23 = 15 Gy and EQD23 = 35 Gy. Planning target volume (PTV), conformity index, rectal width and prescription dose were not significant when adjusted for false discovery rate. Number of beams, beam energy, treatment beam definition, positioning orientation, rectum-PTV separation, rectal length and mean cross sectional area did not affect the risk of toxicities. Conclusions: The RADAR study dataset has allowed an assessment of technical modifications on gastrointestinal toxicity. A number of interesting associations were subsequently found and some factors, previously hypothesised to influence toxicity, did not demonstrate any significant impact. We recommend trial registries be encouraged to record technical modifications introduced during the trial in order for more powerful evidence to be gathered regarding the impact of the interventions.

DOI 10.1186/s13014-014-0282-7
2014 Ebert MA, Gulliford SL, Buettner F, Foo K, Haworth A, Kennedy A, et al., 'Two non-parametric methods for derivation of constraints from radiotherapy dose-histogram data', PHYSICS IN MEDICINE AND BIOLOGY, 59 N101-N111 (2014) [C1]
DOI 10.1088/0031-9155/59/13/N101
Citations Scopus - 1Web of Science - 1
2014 Galvao DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, et al., 'A Multicentre Year-long Randomised Controlled Trial of Exercise Training Targeting Physical Functioning in Men with Prostate Cancer Previously Treated with Androgen Suppression and Radiation from TROG 03.04 RADAR', EUROPEAN UROLOGY, 65 856-864 (2014) [C1]
DOI 10.1016/j.eururo.2013.09.041
Citations Scopus - 25Web of Science - 17
2014 Sharpley CF, Bitsika V, Denham JW, 'Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial', Psycho-Oncology, 23 524-530 (2014) [C1]

Objectives To identify the factors underlying prostate cancer (PCa) patients' depression-anxiety, sexual problems, urinary dysfunction and androgen deprivation therapy (ADT)-linke... [more]

Objectives To identify the factors underlying prostate cancer (PCa) patients' depression-anxiety, sexual problems, urinary dysfunction and androgen deprivation therapy (ADT)-linked breast changes and hot flushes, and test these as predictors of loss of masculinity (LoM) over 36months following diagnosis. Methods One thousand seventy patients from the TROG 03.04 (RADAR) trial the EORTC QLQ C-30 and PR 25 questionnaires, and the International Prostate Cancer Symptom Score of the American Urological Association at baseline, 3, 7, 12, 18, 24 and 36months. Selected items from these scales were factor-analysed to identify a four-component solution for responses at 18 and 36months, and these components were regressed against a single-item measuring LoM. Results Depression-anxiety factor was the most powerful predictor of LoM at both time points, followed by sexual problems of ADT side effects (breast changes and hot flushes). Urinary dysfunction was not a consistent predictor of LoM. Depression-anxiety was also the most significant factor distinguishing between those men who reported LoM and those who did not. Conclusions Although LoM is often reported as arising from ADT, the relative power of depression-anxiety in predicting LoM, both at the selected time points and using a time-lagged analysis, plus the finding that depression-anxiety was the most consistent difference between men who reported LoM and those who did not, argues for the presence of adverse mood states as being the key ingredient in deciding if PCa patients experience loss of their feelings of masculinity. Copyright © 2013 John Wiley & Sons, Ltd. Copyright © 2013 John Wiley & Sons, Ltd.

DOI 10.1002/pon.3448
Citations Scopus - 3Web of Science - 1
2014 Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer', BJU International, 114 344-353 (2014) [C1]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men wit... [more]

Objective To study the influence of adjuvant androgen suppression and bisphosphonates on incident vertebral and non-spinal fracture rates and bone mineral density (BMD) in men with locally advanced prostate cancer. Patients and Methods Between 2003 and 2007, 1071 men with locally advanced prostate cancer were randomly allocated, using a 2 × 2 trial design, to 6 months i.m. leuprorelin (androgen suppression [AS]) before radiotherapy alone ± 12 months additional leuprorelin ± 18 months zoledronic acid (ZdA), commencing at randomization. The main endpoint was incident thoraco-lumbar vertebral fractures, which were assessed radiographically at randomization and at 3 years, then reassessed by centralized review. Subsidiary endpoints included incident non-spinal fractures, which were documented throughout follow-up, and BMD, which was measured in 222 subjects at baseline, 2 years and 4 years. Results Incident vertebral fractures at 3 years were observed in 132 subjects. Their occurrence was not increased by 18 months' AS, nor reduced by ZdA. Incident non-spinal fractures occurred in 72 subjects and were significantly related to AS duration but not to ZdA. Osteopenia and osteoporosis prevalence rates at baseline were 23.4 and 1.4%, respectively, at the hip. Treatment for 6 and 18 months with AS caused significant reductions in hip BMD at 2 and 4 years (P < 0.01) and ZdA prevented these losses at both time points. Conclusion In an AS-naïve population, 18 months of ZdA treatment prevented the sustained BMD losses caused by 18 months of AS treatment; however, the study power was insufficient to show that AS duration or ZdA influenced vertebral fracture rates. © 2013 The Authors. BJU International © 2013 BJU International.

DOI 10.1111/bju.12497
Citations Scopus - 6Web of Science - 8
Co-authors Patrick Mcelduff, Pablo Moscato, Catherine Deste, Allison Steigler
2014 Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al., 'Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial', LANCET ONCOLOGY, 15 1076-1089 (2014) [C1]
DOI 10.1016/S1470-2045(14)70328-6
Citations Scopus - 18Web of Science - 4
Co-authors Christopher Oldmeadow, Allison Steigler, John Attia
2014 Chang D, Joseph DJ, Ebert MA, Galvão DA, Taaffe DR, Denham JW, et al., 'Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer', Journal of Medical Imaging and Radiation Oncology, 58 223-228 (2014) [C1]

Introduction Aging skeletal muscle is associated with not only a reduction in muscle size and strength but also in muscle quality which reflects an increase in fatty infiltration ... [more]

Introduction Aging skeletal muscle is associated with not only a reduction in muscle size and strength but also in muscle quality which reflects an increase in fatty infiltration of muscle. In men with prostate cancer, androgen deprivation therapy (ADT) accelerates this loss of muscle size and strength, but it is unknown if muscle quality is also adversely affected. Therefore, we examined the effects of ADT on muscle attenuation, an indirect measure of intramuscular lipid content, as well as the muscle cross-sectional area (CSA) in men with prostate cancer. Methods Pre- and post-CT scans of the pelvis in 39 men aged 49-78 years receiving leuprorelin were examined. The time between baseline and follow-up scans was 14.6-20 weeks after the commencement of ADT. Changes in skeletal muscle attenuation in Hounsfield units of the rectus femoris and the CSA of the rectus femoris, sartorius and quadricep muscles were assessed. Results Muscle attenuation of the rectus femoris muscle was significantly reduced following the initiation of ADT by 18.9% (P < 0.001). In addition, there was a significant decrease (P < 0.001) in the CSA for the sartorius, quadriceps and rectus femoris muscles. There was no effect of Zometa on muscle attenuation or muscle CSA. Conclusions Our results indicate that not only muscle size but also muscle quality may be adversely affected by the undertaking of ADT in men with prostate cancer. Consequently, interventions to counteract deteriorations to both muscle mass and possibly muscle quality should be considered in men receiving ADT. © 2013 The Royal Australian and New Zealand College of Radiologists.

DOI 10.1111/1754-9485.12124
Citations Scopus - 6Web of Science - 2
2014 Moseshvili E, Joseph DJ, Spry NA, Cohen RJ, Abreu A, Kautto A, Denham JW, 'Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: Pitfalls of its use as an early surrogate marker for bone metastasis', Journal of Medical Imaging and Radiation Oncology, 58 497-502 (2014) [C1]

Introduction Procollagen 1 amino-terminal propeptide (P1NP) is a bone formation marker and has been shown to have a strong association with the extent of bone metastases (BM) in p... [more]

Introduction Procollagen 1 amino-terminal propeptide (P1NP) is a bone formation marker and has been shown to have a strong association with the extent of bone metastases (BM) in patients with advanced prostate cancer. More recently, its levels were found to be affected by androgen deprivation therapies and bisphosphonates. We investigated the role of P1NP as a surrogate marker of sub-radiological skeletal metastases in prostate cancer patients with biochemical failure (BF). Methods BePrepared is a prospective longitudinal substudy of RADAR trial in which serial P1NPs were collected at regular intervals for 123 patients who had completed RADAR protocol treatment. Results There was no trend identified in P1NP levels prior to diagnosis of BM. We found that there was no difference in P1NP concentrations at the time of diagnosis of BM in the group that developed BM compared with P1NP levels in groups with only nodal metastases or BF. In the group of patients who did not experience BF, P1NP was affected by previous luteinizing hormone-releasing hormone-agonist and bisphosphonate therapy. Hence, patients who received an 18-month course of androgen deprivation without bisphosphonates had significantly higher P1NP values than patients with shorter androgen deprivation therapy (ADT) course combined with a course of bisphosphonates. Conclusion P1NP is not a sensitive serum marker of early BM in high-risk prostate cancer patients with BF and low prostate-specific antigen levels as its levels are affected by prior history of bone remodelling therapies such as ADT and bisphosphonates. © 2014 The Royal Australian and New Zealand College of Radiologists.

DOI 10.1111/1754-9485.12134
Citations Scopus - 1Web of Science - 1
2014 Hauer-Jensen M, Denham JW, Andreyev HJN, 'Radiation enteropathy-Pathogenesis, treatment and prevention', Nature Reviews Gastroenterology and Hepatology, 11 470-479 (2014) [C1]

Changes in cancer incidence and mortality have been modest during the past several decades, but the number of cancer survivors has almost tripled during the same period. With an i... [more]

Changes in cancer incidence and mortality have been modest during the past several decades, but the number of cancer survivors has almost tripled during the same period. With an increasing cohort of cancer survivors, efforts to prevent, diagnose and manage adverse effects of cancer therapy, in general, and those of radiation therapy specifically, have intensified. Many cancer survivors have undergone radiation therapy of tumours in the pelvis or abdomen, thus rendering the bowel at risk of injury. In fact, the current prevalence of patients who have long-term radiation-induced intestinal adverse effects exceeds that of IBD. Considerable progress towards reducing toxicity of radiation therapy has been made by the introduction of so-called dose-sculpting treatment techniques, which enable precise delivery of the radiation beam. Moreover, new insights into the underlying pathophysiology have resulted in an improved understanding of mechanisms of radiation-induced bowel toxicity and in development of new diagnostic strategies and management opportunities. This Review discusses the pathogenesis of early and delayed radiation-induced bowel toxicity, presents current management options and outlines priorities for future research. By adding insight into molecular and cellular mechanisms of related bowel disorders, gastroenterologists can substantially strengthen these efforts. © 2014 Macmillan Publishers Limited. All rights reserved.

DOI 10.1038/nrgastro.2014.46
Citations Scopus - 19Web of Science - 13
2014 Sharpley CF, Bitsika V, Christie DRH, Denham JW, Duchesne GM, Couper JW, 'Researching depression in prostate cancer patients: Factors, timing, and measures', Journal of Men's Health, 11 145-156 (2014) [C1]

© Mary Ann Liebert, Inc. Background: Due to the pressing need to understand the causal and associative factors of depression among prostate cancer (PCa) patients, a comprehensive... [more]

© Mary Ann Liebert, Inc. Background: Due to the pressing need to understand the causal and associative factors of depression among prostate cancer (PCa) patients, a comprehensive research protocol for investigating depression in prostate cancer patients is suggested as a way of furthering the collection of data in consistent and informative ways. Methods: A detailed review of a range of predictors of, and buffers against, depression, plus methods of assessing depressive symptomatology and optimum time to collect data were used to develop a model for a comprehensive research protocol. Results: A model protocol is described that includes socioeconomic, genetic, endocrinal, immunological, physiological, psychological, relationship, and socioeconomic pathways to depression. In addition, methods of assessing depressive symptomatology are described, plus comorbidity of anxiety with depression, male depression, and the construct of Individual Burden of Illness for Depression. The need to collect multiple measures over time in order to describe variability in symptoms and the relationships between symptoms and other variables is emphasized. Conclusion: This model protocol of research into depression in prostate cancer patients allows for a comprehensive approach that includes predictors, symptoms, and time for observation. Use of this protocol will enhance the understanding and treatment of depression in PCa patients from a "personalized medicine" perspective.

DOI 10.1089/jomh.2014.0036
Citations Scopus - 1
2013 Denham JW, Hauer-Jensen M, 'Radiation induced bowel injury: A neglected problem', The Lancet, 382 2046-2047 (2013)
DOI 10.1016/S0140-6736(13)61946-7
Citations Scopus - 2
2013 Denham JW, Steigler A, Tai K, Joseph D, Matthews J, Atkinson C, et al., 'Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer', Radiotherapy and Oncology, 107 123-128 (2013) [C1]
DOI 10.1016/j.radonc.2013.03.025
Citations Scopus - 3Web of Science - 2
Co-authors Allison Steigler
2013 Ghose S, Denham J, Ebert M, Kennedy A, Mitra J, Rose S, Dowling J, 'Multi-atlas and Gaussian mixture modeling based perirectal fat segmentation from CT images', Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 8198 LNCS 194-202 (2013)

Accurate perirectal fat segmentation in CT images aids in estimating radiation dose delivered to the region of fat around the rectum during radiation therapy treatment of prostate... [more]

Accurate perirectal fat segmentation in CT images aids in estimating radiation dose delivered to the region of fat around the rectum during radiation therapy treatment of prostate cancer. Such a process is important in determining the resulting toxicity of the neighboring tissues. However automatic or semi-automatic segmentation of the perirectal fat in CT images is a challenging task due to inter patient anatomical variability, contrast variability and imaging artifacts. We propose a combined schema of multi-atlas and multi parametric Gaussian mixture modeling for perirectal fat segmentation in CT images. Multi-atlas based soft segmentation and multi parametric Gaussian mixture modeling aids in identifying the volume of interest (VOI). Thereafter expectation maximization (EM) based soft clustering of the intensities of the VOI refined with positional probabilities of the perirectal fat provides the segmentation of the perirectal fat. The proposed method achieves a mean sensitivity value of 0.88±0.07 and a mean specificity value of 0.998±0.001 with 5 patient datasets in a leave-one-patient-out validation framework. Qualitative results show a good approximation of the perirectal fat volume compared to the ground truth. © 2013 Springer-Verlag.

DOI 10.1007/978-3-642-41083-3_22
2013 Singh J, Greer PB, White MA, Parker J, Patterson J, Tang CI, et al., 'Treatment-Related Morbidity in Prostate Cancer: A Comparison of 3-Dimensional Conformal Radiation Therapy With and Without Image Guidance Using Implanted Fiducial Markers', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 85 1018-1023 (2013) [C1]
DOI 10.1016/j.ijrobp.2012.07.2376
Citations Scopus - 13Web of Science - 10
Co-authors Peter Greer
2013 Denham JW, Steigler A, 'Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy', Seminars in Radiation Oncology, 23 206-214 (2013) [C1]
DOI 10.1016/j.semradonc.2013.01.008
Citations Scopus - 3Web of Science - 3
Co-authors Allison Steigler
2013 Kearvell R, Haworth A, Ebert MA, Murray J, Hooton B, Richardson S, et al., 'Quality improvements in prostate radiotherapy: Outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial', Journal of Medical Imaging and Radiation Oncology, 57 247-257 (2013) [C1]
DOI 10.1111/1754-9485.12025
Citations Scopus - 14Web of Science - 8
2012 Wilcox C, Kautto AJ, Steigler A, Denham J, 'Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term', Oncology: International Journal of Cancer Research and Treatment, 82 56-58 (2012) [C1]
Citations Scopus - 9Web of Science - 9
Co-authors Allison Steigler
2012 Denham J, Wilcox C, Lamb DS, Spry NA, Duchesne G, Atkinson C, et al., 'Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer', Radiotherapy and Oncology, 105 184-192 (2012) [C1]
Citations Scopus - 18Web of Science - 14
Co-authors Patrick Mcelduff
2012 Dowling JA, Lambert JA, Parker J, Salvado O, Fripp J, Capp A, et al., 'An atlas-based electron density mapping method for Magnetic Resonance Imaging (MRI)-Alone treatment planning and adaptive MRI-Based prostate radiation therapy', International Journal of Radiation Oncology Biology Physics, 83 E5-E11 (2012) [C1]
Citations Scopus - 57Web of Science - 39
Co-authors Peter Greer
2012 Denham J, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai K-H, et al., 'Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): Secondary endpoints from a randomised phase 3 factorial trial', Lancet Oncology, 13 1260-1270 (2012) [C1]
Citations Scopus - 17Web of Science - 17
Co-authors Patrick Mcelduff
2012 D'Amico AV, Chen M-H, De Castro M, De Castro M, Lamb DS, Steigler A, et al., 'Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: An analysis of two randomised trials', Lancet Oncology, 13 189-195 (2012) [C1]
Citations Scopus - 18Web of Science - 15
Co-authors Allison Steigler
2012 Steigler A, Denham J, Lamb DS, Spry NA, Joseph D, Matthews J, et al., 'Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: Data from the TROG 96.01 trial', Prostate Cancer, 2012 1-11 (2012) [C1]
Co-authors Allison Steigler
2011 Galvao DA, Taaffe DR, Cormie P, Spry N, Chambers SK, Peddle-Mcintyre C, et al., 'Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: A randomized controlled trial', BMC Cancer, 11 517 (2011) [C3]
Citations Scopus - 5Web of Science - 4
2011 Denham J, 'An important piece of the localized prostate cancer puzzle?', Nature Reviews: Clinical Oncology, 8 573-574 (2011) [C3]
DOI 10.1038/nrclinonc.2011.128
2011 Dunstan RH, Sparkes DL, MacDonald MM, Roberts TK, Wratten C, Kumar M, et al., 'Altered amino acid homeostasis and the development of fatigue by breast cancer radiotherapy patients: A pilot study', Clinical Biochemistry, 44 208-215 (2011) [C1]
DOI 10.1016/j.clinbiochem.2010.10.002
Citations Scopus - 3Web of Science - 2
Co-authors Diane Sparkes, Tim Roberts, Hugh Dunstan, Tony Rothkirch, Surinder Baines
2011 Greer PB, Dowling JA, Lambert JA, Fripp J, Parker J, Denham J, et al., 'A magnetic resonance imaging-based workflow for planning radiation therapy for prostate cancer', Medical Journal of Australia, 194 S24-S27 (2011) [C1]
Citations Scopus - 15Web of Science - 9
Co-authors Peter Greer
2011 Andreyev HJN, Wotherspoon A, Denham J, Hauer-Jensen M, ''Pelvic radiation disease': New understanding and new solutions for a new disease in the era of cancer survivorship', Scandinavian Journal of Gastroenterology, 46 389-397 (2011) [C1]
DOI 10.3109/00365521.2010.545832
Citations Scopus - 25Web of Science - 21
2011 Gustafsson H, Vial P, Kuncic Z, Baldock C, Denham J, Greer PB, 'Direct dose to water dosimetry for pretreatment IMRT verification using a modified EPID', Medical Physics, 38 6257-6264 (2011) [C1]
DOI 10.1118/1.3656946
Citations Scopus - 5Web of Science - 3
Co-authors Peter Greer
2011 Harrison KM, Ebert MA, Kron T, Howlett SJ, Cornes D, Hamilton CS, Denham J, 'Design, manufacture, and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison', Medical Physics, 38 5330-5337 (2011) [C1]
DOI 10.1118/1.3626573
Citations Scopus - 13Web of Science - 11
2011 Ebert MA, Harrison KM, Howlett SJ, Cornes D, Bulsara M, Hamilton CS, et al., 'Dosimetric intercomparison for multicenter clinical trials using a patient-based anatomic pelvic phantom', Medical Physics, 38 5167-5175 (2011) [C1]
DOI 10.1118/1.3626484
Citations Scopus - 11Web of Science - 11
2011 Hatton J, Greer PB, Tang C, Wright P, Capp A, Gupta S, et al., 'Does the planning dose-volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans', Radiotherapy and Oncology, 98 162-168 (2011) [C1]
DOI 10.1016/j.radonc.2011.01.006
Citations Scopus - 34Web of Science - 26
Co-authors Peter Greer, Joan Hatton
2011 Lambert JA, Greer PB, Menk FW, Patterson J, Parker J, Dahl K, et al., 'MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning', Radiotherapy and Oncology, 98 330-334 (2011) [C1]
DOI 10.1016/j.radonc.2011.01.012
Citations Scopus - 42Web of Science - 27
Co-authors Peter Greer, Fred Menk
2011 Ebert MA, Lamb DS, Joseph DJ, Steigler A, Denham J, 'A methodology for the analysis of PSA response signatures', Radiotherapy and Oncology, 98 198-202 (2011) [C1]
DOI 10.1016/j.radonc.2010.11.013
Citations Scopus - 1
Co-authors Allison Steigler
2011 Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'Another form of subgroup to beware', Radiotherapy and Oncology, 101 525-526 (2011) [C3]
DOI 10.1016/j.radonc.2011.08.032
Citations Scopus - 1Web of Science - 1
Co-authors Catherine Deste, Allison Steigler
2011 Lamb DS, Denham J, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: Analysis of data from the TROG 96.01 randomized trial', International Journal of Radiation Oncology Biology Physics, 79 385-391 (2011) [C1]
DOI 10.1016/j.ijrobp.2009.10.071
Citations Scopus - 17Web of Science - 13
Co-authors Catherine Deste, Allison Steigler
2011 D'Amico AV, Chen MH, Crook J, Armstrong JG, Malone S, Steigler A, et al., 'Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer', Journal of Clinical Oncology, 29 4682-4687 (2011) [C1]
DOI 10.1200/jco.2011.37.0726
Citations Scopus - 5Web of Science - 5
Co-authors Allison Steigler
2011 Denham J, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al., 'Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial', The Lancet Oncology, 12 451-459 (2011) [C1]
DOI 10.1016/s1470-2045(11)70063-8
Citations Scopus - 140Web of Science - 111
Co-authors Allison Steigler, Catherine Deste
2010 Denham J, Bender R, Paradice WEJ, 'It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials', Medical Journal of Australia, 192 393-396 (2010) [C1]
Citations Scopus - 7Web of Science - 10
2010 Delahunt B, Lamb DS, Srigley JR, Murray JD, Wilcox C, Samaratunga H, et al., 'Gleason scoring: A comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point', Pathology, 42 339-343 (2010) [C1]
DOI 10.3109/00313021003787924
Citations Scopus - 26Web of Science - 20
2010 Baumann M, Holscher T, Denham J, 'Fractionation in prostate cancer - Is it time after all?', Radiotherapy and Oncology, 96 1-5 (2010) [C3]
Citations Scopus - 8Web of Science - 7
2010 Kumar M, Denham J, Steigler A, 'Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: The jury must remain out', Journal of Clinical Oncology, 28 E445-E446 (2010) [C3]
DOI 10.1200/JCO.2010.29.4868
Citations Scopus - 1Web of Science - 1
Co-authors Allison Steigler
2010 Andreyev HJN, Wotherspoon A, Denham J, Hauer-Jensen M, 'Defining pelvic-radiation disease for the survivorship era', Lancet Oncology, 11 310-312 (2010) [C3]
Citations Scopus - 36Web of Science - 33
2009 Galvao DA, Spry NA, Taaffe DR, Denham J, Joseph D, Lamb DS, et al., 'A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial', BMC Cancer, 9 1-7 (2009) [C1]
DOI 10.1186/1471-2407-9-419
Citations Scopus - 21Web of Science - 20
2009 Gupta SA, Wratten C, Kilmurray J, Nash S, Seldon M, O'Brien P, et al., 'Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? A prospective study', Asia-Pacific Journal of Clinical Oncology, 5 257-263 (2009) [C1]
DOI 10.1111/j.1743-7563.2009.01236.x
Citations Scopus - 1Web of Science - 1
2009 Ebert M, Harrison K, Cornes D, Howlett S, Joseph D, Kron T, et al., 'Comprehensive Australasian multicentre dosimetric intercomparison: Issues, logistics and recommendations', Journal of Medical Imaging and Radiation Oncology, 53 119-131 (2009) [C1]
DOI 10.1111/j.1754-9485.2009.02047.x
Citations Scopus - 18Web of Science - 15
2009 Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?', Cancer, 115 4477-4487 (2009) [C1]
DOI 10.1002/cncr.24484
Citations Scopus - 18Web of Science - 17
Co-authors Allison Steigler, Catherine Deste
2009 Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'PSA response signatures: A powerful new prognostic indicator after radiation for prostate cancer?', Radiotherapy and Oncology, 90 382-388 (2009) [C1]
DOI 10.1016/j.radonc.2008.10.004
Citations Scopus - 13Web of Science - 12
Co-authors Catherine Deste, Allison Steigler
2009 Haworth A, Kearvell R, Greer PB, Hooton B, Denham J, Lamb D, et al., 'Assuring high quality treatment delivery in clinical trials: Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 'RADAR' set-up accuracy study', Radiotherapy and Oncology, 90 299-306 (2009) [C1]
DOI 10.1016/j.radonc.2008.10.011
Citations Scopus - 24Web of Science - 20
Co-authors Peter Greer
2009 Lincz L, Gupta SA, Wratten C, Kilmurray J, Nash S, Seldon M, et al., 'Thrombin generation as a predictor of radiotherapy induced skin erythema', Radiotherapy and Oncology, 90 136-140 (2009) [C1]
DOI 10.1016/j.radonc.2008.10.002
Citations Scopus - 2Web of Science - 1
Co-authors Lisa Lincz
2009 Capp A, Inostroza-Ponta M, Bill D, Moscato PA, Lai C, Christie D, et al., 'Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial', Radiotherapy and Oncology, 90 400-407 (2009) [C1]
DOI 10.1016/j.radonc.2008.09.019
Citations Scopus - 44Web of Science - 38
Co-authors Pablo Moscato, Allison Steigler
2009 Denham J, Kumar M, Gleeson PS, Lamb DS, Joseph D, Atkinson C, et al., 'Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer', International Journal of Radiation Oncology Biology Physics, 74 404-411 (2009) [C1]
DOI 10.1016/j.ijrobp.2008.08.047
Citations Scopus - 8Web of Science - 6
Co-authors Peter Greer, Catherine Deste, Allison Steigler
2009 Denham J, Steigler A, Kumar M, Lamb DS, Joseph D, Spry NA, et al., 'Measuring time to biochemical failure in the Trog 96.01 trial: When should the clock start ticking?', International Journal of Radiation Oncology Biology Physics, 75 1008-1012 (2009) [C1]
DOI 10.1016/j.ijrobp.2008.12.085
Citations Scopus - 5Web of Science - 3
Co-authors Allison Steigler, Peter Greer, Catherine Deste
2009 Lamb DS, Delahunt B, Denham J, Slaney D, 'Survival benefit confirmed for prostate cancers diagnosed by PSA testing', New Zealand Medical Journal, 122 67-70 (2009) [C3]
2008 Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial', Lancet Oncology, 9 1058-1068 (2008) [C1]
DOI 10.1016/s1470-2045(08)70236-5
Citations Scopus - 45Web of Science - 37
Co-authors Catherine Deste, Peter Greer, Allison Steigler
2008 Gupta SA, Wratten C, Ludbrook JJ, O'Brien PC, Kumar MB, Denham JW, 'Hypofractionated versus standard fractionation radiotherapy in early glottic cancer: A retrospective review', Asia-Pacific Journal of Clinical Oncology, 4 239-243 (2008) [C1]
DOI 10.1111/j.1743-7563.2008.00216.x
2008 Greer PB, Dahl K, Ebert MA, White M, Wratten C, Ostwald PM, et al., 'Assessment of a daily online implanted fiducial marker-guided prostate radiotherapy process', Journal of Medical Imaging and Radiation Oncology, 52 517-524 (2008) [C1]
DOI 10.1111/j.1440-1673.2008.02006.x
Citations Scopus - 5Web of Science - 4
Co-authors Peter Greer, Patricia Ostwald
2008 Greer PB, Dahl K, Ebert MA, Wratten C, White M, Denham J, 'Comparison of prostate set-up accuracy and margins with off-line bony anatomy corrections and online implanted fiducial-based corrections', Journal of Medical Imaging and Radiation Oncology, 52 511-516 (2008) [C1]
DOI 10.1111/j.1440-1673.2008.02005.x
Citations Scopus - 17Web of Science - 16
Co-authors Peter Greer
2008 Ebert MA, Howlett SJ, Harrison K, Cornes D, Hamilton CS, Denham J, 'Linear-accelerator X-ray output: A multicentre chamber-based intercomparison study in Australia and New Zealand', Australasian Physical & Engineering Sciences in Medicine, 31 268-279 (2008) [C1]
DOI 10.1007/BF03178596
Citations Scopus - 8Web of Science - 4
2007 Madjar I, Denham J, Rashid P, 'Do women have a role in early detection of prostate cancer? - Lessons from a qualitative study', Australian Family Physician, 36 375-377 (2007) [C1]
Citations Scopus - 5Web of Science - 4
2007 D'Amico AV, Denham J, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al., 'Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions', Journal of Clinical Oncology, 25 2420-2425 (2007) [C1]
DOI 10.1200/JCO.2006.09.3369
Citations Web of Science - 274
Co-authors Allison Steigler
2007 Hauer-Jensen M, Wang J, Boerma M, Fu Q, Denham J, 'Radiation damage to the gastrointestinal tract: Mechanisms, diagnosis, and management', Current Opinion in Supportive and Palliative Care, 1 23-29 (2007) [C1]
DOI 10.1097/SPC.0b013e3281108014
2007 Wratten C, O'Brien PC, Hamilton CS, Bill D, Kilmurray J, Denham J, 'Breast edema in patients undergoing breast-conserving treatment for breast cancer: Assessment via high frequency ultrasound', Breast Journal, 13 266-273 (2007) [C1]
DOI 10.1111/j.1524-4741.2007.00420.x
Citations Scopus - 11Web of Science - 10
2007 Madjar I, Kacen L, Ariad S, Denham J, 'Telling their stories, telling our stories: Physicians' experiences with patients who decide to forgo or stop treatment for cancer', Qualitative Health Research, 17 428-441 (2007) [C1]
DOI 10.1177/1049732306298806
Citations Web of Science - 6
2007 D'Amico AV, Denham J, Bolla M, Collette L, Lamb DS, Tai KH, et al., 'Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate', Cancer, 109 2004-2010 (2007) [C1]
DOI 10.1002/cncr.22628
Citations Scopus - 24Web of Science - 21
Co-authors Allison Steigler
2007 Denham J, 'MRC RT01: an important trial', Lancet Oncology, 8 459-460 (2007) [C3]
DOI 10.1016/s1470-2045(07)70152-3
Citations Scopus - 2Web of Science - 2
2006 Dempsey CL, Duggan LJ, Bazley SG, Denham J, Kron T, 'Miniature LiF:Mg,Cu,P TLDs to study the effect of applicator material in 192-Ir brachytherapy', Australasian Physical & Engineering Sciences in Medicine, 29 300-302 (2006) [C1]
DOI 10.1007/BF03178394
Citations Scopus - 2
Co-authors Claire Dempsey, Lisa Duggan
2005 Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, et al., 'Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation', Radiotherapy and oncology, 77 117-125 (2005) [C1]
DOI 10.1016/j.radonc.2005.10.005
Citations Scopus - 41Web of Science - 34
Co-authors Catherine Deste, Allison Steigler
2005 Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M, et al., 'Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).', Journal of Clinical Oncology, 23 79-87 (2005) [C1]
DOI 10.1200/JCO.2005.01.072
Citations Web of Science - 157
2005 Lamb DS, Denham JW, Delahunt B, 'Prostate cancer screening in Australasia', Clinical Oncology, 17 231-233 (2005) [C1]
DOI 10.1016/j.clon.2005.03.005
Citations Scopus - 6Web of Science - 5
2005 Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al., 'Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial', Lancet Oncology, 6 659-668 (2005) [C1]
DOI 10.1016/s1470-2045(05)70288-6
Citations Scopus - 503Web of Science - 403
Co-authors Stephen Ackland
2005 Denham J, Steigler A, Lamb D, Joseph D, Mameghan H, Turner S, et al., 'Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer : results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial', The Lancet, 6 841-850 (2005) [C1]
DOI 10.1016/S1470-2045(05)70348-X
Citations Scopus - 283Web of Science - 239
Co-authors Catherine Deste, Allison Steigler
2004 Tsang G, O'Brien P, Robertson R, Hamilton C, Wratten C, Denham J, 'All Delays before radiotherapy risk progression of Merkel cell carcinoma', Australasian Radiology, 48 371-375 (2004) [C1]
DOI 10.1111/j.0004-8461.2004.01321.x
Citations Scopus - 22
2004 Wratten C, Denham J, Kron T, O'Brien P, Hamilton C, ''When measurements mean action' decision models for portal image review to eliminate systematic set-up errors', Australasian Radiology, 48 272-279 (2004) [C1]
DOI 10.1111/j.1440-1673.2004.01288.x
Citations Scopus - 4
2004 O'Brien P, Hamilton C, Denham J, Gourlay R, Franklin IV, 'Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer', International Journal of Radiation: Oncology- Biology- Physics, 58 75-80 (2004) [C1]
DOI 10.1016/S0360-3016(03)01445-7
Citations Scopus - 51Web of Science - 40
2004 Wratten C, Kilmurray J, Nash S, Seldon M, Hamilton C, O'Brien P, Denham J, 'Fatigue during breast radiotherapy and its relationship to biological factors', International Journal of Radiation: Oncology- Biology- Physics, 59 160-167 (2004) [C1]
DOI 10.1016/j.ijrobp.2003.10.008
Citations Scopus - 86Web of Science - 69
2003 Daly T, Poulsen MG, Denham JW, Peters LJ, Lamb DS, Krawitz H, et al., 'The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck', RADIOTHERAPY AND ONCOLOGY, 68 113-122 (2003)
DOI 10.1016/S0167-8140(03)00198-1
Citations Scopus - 21Web of Science - 17
2003 Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, et al., 'Acceptability of short term neo-adjuvant deprivation in patients with locally advanced prostate cancer', Radiotherapy and Oncology, 68 255-267 (2003) [C1]
DOI 10.1016/S0167-8140(03)00193-2
Citations Scopus - 32Web of Science - 27
2003 Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
DOI 10.1053/clon.2003.0212
Citations Scopus - 35Web of Science - 32
Co-authors Stephen Ackland, Allison Steigler
2003 Denham JW, 'Clinical implications of mucosal regeneration', INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 79 511-512 (2003)
DOI 10.1080/713760551
2003 Denham JW, 'Clinical implications of mucosal regeneration', International Journal of Radiation Biology, 79 1-2 (2003) [C1]
2003 Bentzen SM, D Rr W, Anscher MS, Denham J, Hauer-Jensen M, Marks LB, Williams J, 'Normal tissue effects: Reporting and analysis', Seminars in Radiation Oncology, 13 189-202 (2003) [C1]
DOI 10.1016/s1053-4296(03)00036-5
Citations Scopus - 93Web of Science - 83
2003 Hauer-Jensen M, Wang J, Denham J, 'Bowel injury: Current and evolving management strategies', Seminars in Radiation Oncology, 13 358-371 (2003) [C1]
DOI 10.1016/s1053-4296(03)00032-8
Citations Web of Science - 57
2002 Hood C, Duggan L, Bazley SG, Denham J, Budzanowski M, Kron T, 'LiF: Mg, Cu, P 'Pin Worms': Miniature Detectors for Brachytherapy Dosimetry', Radiation Protection Dosimetry, 101(1-4) 407-410 (2002) [C1]
Citations Scopus - 7Web of Science - 8
2002 Denham J, Hauer-Jensen M, 'The radiotherapeutic injury - a complex 'wound'', Radiotherapy and Oncology, 63 129-145 (2002) [C1]
Citations Scopus - 267Web of Science - 240
2002 Denham JW, Hauer-Jensen M, Peters LJ, 'In regard to Denham et al., Is it time for a new formalism to categorize normal tissue radiation injury? IJROBP 2001;50 : 1105-1106 - Response', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 52 1148-1148 (2002)
DOI 10.1016/S0360-3016(01)02745-6
2002 Denham JW, 'In response to Seymour and colleagues (Letter)', Int. J. Radiat. Oncol. Biol. Phys., 52 (2002) [C3]
2002 Denham J, 'Prostate Cancer: Low the only consideration? In regard to Fowler, Chappell, and Ritter: The prospects for new treatments for prostate cancer', Int. J. Radiation Oncology Biol. Phys., 53(5) 1394-1395 (2002) [C3]
Citations Scopus - 1Web of Science - 2
2002 Denham JW, 'Prostate cancer: low alpha/beta the only consideration? (Letter to the Editor)', Int.J.Radiat.Onco.Biol.Phys., 52 3-5 (2002) [C3]
2002 Kron T, Hamilton C, Roff M, Denham J, 'Dosimetric Intercomparison for Two Australasian Clinical Trials Using an Anthropomorphic Phantom', International Journal of Radiation: Oncology - Biology - Physics, 52(2) 566-579 (2002) [C1]
Citations Scopus - 29Web of Science - 23
2002 O'Brien P, Franklin C, Poulsen M, Joseph D, Spry N, Denham J, 'Acute Symptoms, Not Rectally Administered Sucralfate, Predict for Late Radiation Proctitis: Longer Term Follow-up of a Phase III Trial - Trans-Tasman Radiation Oncology Group', International Journal of Radiation: Oncology - Biology - Physics, 54(2) 442-449 (2002) [C1]
Citations Scopus - 65Web of Science - 54
2002 Dorr W, Hamilton C, Boyd T, Reed BE, Denham J, 'Radiation-Induced Changes in Cellularity and Proliferation in Human Oral Mucosa', International Journal of Radiation: Oncology - Biology - Physics, 52(4) 911-917 (2002) [C1]
Citations Scopus - 76Web of Science - 63
2002 Denham JW, 'Prostate cancer: low alpha/beta the only consideration? (2002) [C1]
2002 Denham JW, Hauer-Jensen M, Peters LJ, 'In response to Seymour and colleagues (2002) [C1]
2002 Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, et al., 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10) 2017-2020 (2002) [C1]
Citations Scopus - 22Web of Science - 23
Co-authors Stephen Ackland, Lisa Lincz, Jennette Sakoff
2001 Denham J, 'Wigg and Morgan;'New'hope?', Australasian Radiology, 45 541 (2001) [C3]
2001 Poulson M, Denham J, Pesters L, Lamb D, Spry N, Hindley A, et al., 'A randomised trial of accelerated and conventional radiotherapy for stage III and IV sqamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study', Radiotherapy and Oncology, 60 113-122 (2001) [C1]
Citations Scopus - 78Web of Science - 71
2001 Denham J, Kron T, 'Extinction of the Weakest', International Journal of Radiation Oncology Biology Physics, 51 807-819 (2001) [C1]
Citations Scopus - 6Web of Science - 6
2001 Denham J, Hauer-Jensen M, Peters L, 'Is it time for a new formalism to categorize normal tissue radiation injury', International Journal of Radiation Oncology, Biology & Physics, 50 1105-1106 (2001) [C3]
Citations Scopus - 44Web of Science - 40
2000 Wratten C, Kilmurray J, Wright S, O'Brien P, Back M, Hamilton C, Denham J, 'Pilot Study of High-Frequency Ultrasound to Assess Cutaneous Oedema in the Conservatively Managed Breast', International Journal of Cancer, 90 295-301 (2000) [C1]
Citations Scopus - 8Web of Science - 8
2000 Duggan L, Butson M, Howlett S, Denham J, Kron T, 'Verificationo f the dose distribution for 192Ir moult treatments using radiochromic film and LiF:Mg,Cu,P TLDs', Australasian Physical and Engineering Sciences in Medicine, 23 15-20 (2000) [C1]
Citations Scopus - 6
2000 Denham J, Kron T, Hamilton C, 'A TIMELY REMINDER', RADIOTHERAPY AND ONCOLOGY, 56 129-130 (2000) [C3]
Citations Scopus - 2Web of Science - 2
2000 Denham J, Hauer-Jensen M, Kron T, Langberg C, 'TREATMENT-TIME-DEPENDENCE MODELS OF EARLY AND DELAYED RADIATION INJURY IN RAT SMALL INTESTINE', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48 871-887 (2000) [C1]
Citations Scopus - 25Web of Science - 22
2000 Denham JW, 'Influence of dose-rate on the inflammatory damage and adhesion molecule expression after abdominal radiation in the rat', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 47 1460-1460 (2000)
DOI 10.1016/S0360-3016(00)00533-2
Citations Scopus - 1Web of Science - 2
2000 Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I, et al., 'A quality assurance audit: Phase 111 trial of maximal androgen deprivation in prostate cancer (TROG 96.01)', AUSTRALASIAN RADIOLOGY, 44 65-71 (2000) [C1]
Citations Scopus - 12
Co-authors Allison Steigler
2000 See A, Kron T, Johansen J, Hamilton C, Bydder S, Hawkins J, et al., 'Decision-making models in the analysis of portal films: A clinical pilot study', Australasian Radiology, 44 77-83 (2000) [C1]
Citations Scopus - 17
1999 Poulsen M, Denham J, Spry N, Lamb D, Peters L, Krawitz H, et al., 'Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: A Trans-Tasman Radiation Oncology Group study', Australasian Radiology, 43 487-494 (1999)

The primary purpose of the present analysis was to assess the feasibility and acute toxicity of a pure accelerated fractionation regimen in a cooperative group setting. This analy... [more]

The primary purpose of the present analysis was to assess the feasibility and acute toxicity of a pure accelerated fractionation regimen in a cooperative group setting. This analysis included the first 320 patients entered on to the Trans-Tasman Radiation Oncology Group (TROG) randomized controlled trial which compared accelerated radiotherapy (ART) with conventional radiotherapy (CRT) in stage III and IV squamous cell carcinoma (SCC) of the head and neck. Patients were randomized to either 59.4 Gy in 33 fractions over 24 days (ART) or to 70 Gy 35 fractions over 49 days (CRT) after being stratified for site and stage. Accrual began in 1991 and the trial was closed on 3 April 1998 with the targeted 350 patients. The 3-year survival for the whole group was 54%, and the 3-year disease-free survival was 41%. Toxicity data were available on 303 patients (148 ART; 155 CRT). Mucosal toxicity was worse in the accelerated arm, and it peaked ~ 3 weeks earlier than the conventional arm. Skin toxicity was equivalent but occurred ~ 7 days earlier in the accelerated arm. Acute effects in both arms healed completely. Hospitalization was more common in the ART arm (71 vs 52 patients; P = 0.01) but the total bed days in hospital was not greatly different (1707 bed days for ART and 1607 bed days for CRT). Patients were more likely to require nasogastric (NG) feeding in the ART arm (49 vs 33 patients; P = 0.02). There were 1157 NG feeding days for ART and 1154 NG feeding days for CRT. The average cost of radiation treatment per patient including hospitalization, NG feeding and accommodation was $11 750 in the ART arm and $11 587 in the CRT arm. The accelerated arm has been shown to be a tolerable, practical and cost-equivalent regimen. The assessment of the therapeutic ratio of this accelerated protocol (ART) will be determined when the analysis of late effects and loco-regional control is made when the data are more mature.

DOI 10.1046/j.1440-1673.1999.00718.x
Citations Scopus - 10
1999 Denham JW, Atkinson CH, 'Where is your evidence?', Australasian Radiology, 43 124-125 (1999)
DOI 10.1046/j.1440-1673.1999.00623.x
1999 Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al., 'Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer', Australasian Radiology, 43 220-226 (1999)

The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophospham... [more]

The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophosphamide, methotrexate and fluorouracil (CMF) therapy. Two hundred and sixty eight (268) patients were treated at two Australian and two New Zealand centres between 1981 and July 1995. One hundred and sixty-nine patients underwent conservation surgery and 99 had mastectomies. Median follow-up was 53 months. Conventionally fractionated radiation was delivered simultaneously during the first two cycles of CMF, avoiding radiation on the Fridays that the intravenous components of CMF were delivered. In conservatively treated patients, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 34.5 ± 5.2%, 25.4 ± 4.5% and 75.5 ± 4.8%, respectively. Crude incidence of local relapse at 4 years was 6.3% and at regional/distant sites was 26.3%. Highest grades of granulocyte toxicity (< 0.5 x 109/L), moist desquamation, radiation pneumonitis and persistent breast oedema were recorded in 10.7, 8.5, 8.9 and 17.2%, respectively. In patients treated by mastectomy, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 59.7 ± 7.3%, 56.7 ± 7.4% and 50.1 ± 7%. The crude incidence of local relapse at 4 years was 5.6% and at regional/distant sites it was 45.7%. The issue of appropriate timing of adjuvant therapies has become particularly important with the increasing acknowledgement of the value of anthracycline-based regimens. For women in lower risk categories (e.g. 1-3 nodes positive or node negative), CMF may offer a potentially better therapy, particularly where breast-conserving surgical techniques have been used. In such cases CMF allows the simultaneous delivery of radiotherapy with the result of optimum local control, without compromise or regional or systemic relapse rates. Further randomized trials that directly address the optimal integration of the two modalities, such as the one carried out in Boston, are clearly necessary.

DOI 10.1046/j.1440-1673.1999.00638.x
Citations Scopus - 12
Co-authors Stephen Ackland
1999 Hamilton C, Poulsen M, Walker Q, Krawitz H, Hindley A, Spry N, et al., 'Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01)', Australasian Radiology, 43 227-232 (1999)

The Trans-Tasman Radiation Oncology Group (TROG) initiated a randomized trial, testing accelerated (twice daily) radiotherapy against conventional radiotherapy for stage III and s... [more]

The Trans-Tasman Radiation Oncology Group (TROG) initiated a randomized trial, testing accelerated (twice daily) radiotherapy against conventional radiotherapy for stage III and stage IV squamous cell carcinoma of the head and neck in 1991. In 1996, the Trial Management Committee arranged for a technical audit of 76 cases from 11 institutions, conducted by investigators from interstate institutions. A 10% unacceptable protocol violation rate was detected, which compares favourably with initial Radiation Therapy Oncology Group (RTOG) experience in the late 1970s. Infrastructural deficits with poor quality of documentation, incomplete retrieval of films and document return have been demonstrated in some cases. The Trans-Tasman Radiation Oncology Group is actively pursuing procedural and resourcing issues in order to redress this and is actively expanding its Quality Assurance (QA) Programme with an intercentre dosimetry study. Ultimately, comprehensive clinical and technical QA site visits are planned.

DOI 10.1046/j.1440-1673.1999.00639.x
Citations Scopus - 14
Co-authors Allison Steigler
1999 Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, et al., 'Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?', RADIOTHERAPY AND ONCOLOGY, 52 157-164 (1999)
DOI 10.1016/S0167-8140(99)00107-3
Citations Scopus - 97Web of Science - 92
1999 Denham JW, O'Brien PC, Dunstan RH, Johansen J, See A, Hamilton CS, et al., 'Is there more than one late radiation proctitis syndrome?', Radiotherapy and Oncology, 51 43-53 (1999) [C1]
Citations Scopus - 115Web of Science - 105
Co-authors Hugh Dunstan
1999 Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P, Spry NA, 'Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy', EUROPEAN JOURNAL OF CANCER, 35 921-927 (1999)
DOI 10.1016/S0959-8049(99)00065-9
Citations Scopus - 5Web of Science - 4
Co-authors Stephen Ackland
1998 Back M, Delaney G, Denham J, Graham P, Hamilton C, Morgan G, et al., 'How should we introduce high-dose chemotherapeutic strategies into the adjuvant management of high-risk breast cancer in Australia?', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 68 10-15 (1998)
DOI 10.1111/j.1445-2197.1998.tb04628.x
Citations Scopus - 1Web of Science - 1
1998 Simonen P, Hamilton C, Ferguson S, Ostwald P, O'Brien M, O'Brien P, et al., 'Do inflammatory processes contribute to radiation induced erythema observed in the skin of humans?', RADIOTHERAPY AND ONCOLOGY, 46 73-82 (1998)
DOI 10.1016/S0167-8140(97)00115-1
Citations Scopus - 36Web of Science - 26
1998 Lamb DS, Denham JW, Morum PE, Gray AJ, 'Long-term results of accelerated radiation treatment for advanced head and neck cancer', RADIOTHERAPY AND ONCOLOGY, 49 29-32 (1998)
DOI 10.1016/S0167-8140(98)00078-4
Citations Scopus - 7Web of Science - 4
1998 See A, Wright S, Denham JW, 'A pilot study of Dermofilm in acute radiation-induced desquamative skin reactions', Clinical Oncology, 10 182-185 (1998)

Dermofilm (Innovatec, Australia Pty Ltd) is a topical preparation containing hydrophilic and lipophilic agents that enhance the barrier functions of damaged skin. It has been asse... [more]

Dermofilm (Innovatec, Australia Pty Ltd) is a topical preparation containing hydrophilic and lipophilic agents that enhance the barrier functions of damaged skin. It has been assessed in a pilot study of 50 patients with desquamative skin reactions to establish whether it is a suitable candidate to test against an existing, widely used alternative in a randomized controlled trial. Symptomatic improvement, compliance and healing time were the study endpoints. Symptomatic improvement occurred in 49 patients and compliance with the prescribing instructions was uniform. The range of healing times observed at all sites was large but a relationship with the size of the initial desquamated area was noted. It is concluded that a randomized trial comparing Dermofilm with a widely used and cheaper alternative would require a multicentre effort involving approximately 400 patients (200 per arm). Other trial design considerations are discussed.

DOI 10.1016/S0936-6555(98)80064-2
Citations Scopus - 16
1998 Peng Y, Dear KB, Denham JW, 'Generalized F Mixture Model For Cure Rate Estimation', Statistics in Medicine, 17 813-830 (1998) [C1]
Citations Scopus - 85Web of Science - 84
1997 Burmeister BH, Smithers BM, Denham JW, 'Combined modality therapy for carcinoma of the oesophagus: current status and future directions', MEDICAL JOURNAL OF AUSTRALIA, 167 349-350 (1997)
Citations Web of Science - 4
1997 Denham J, 'Factors influencing outcome following radio-chemotherapy for oesophageal cancer - Response', RADIOTHERAPY AND ONCOLOGY, 42 91-92 (1997)
DOI 10.1016/S0167-8140(96)01855-5
1997 Hamilton CS, Potten CS, Denham JW, OBrien PC, Kron T, Ostwald P, et al., 'Response of human hair cortical cells to fractionated radiotherapy', RADIOTHERAPY AND ONCOLOGY, 43 289-292 (1997)
DOI 10.1016/S0167-8140(97)00059-5
Citations Scopus - 8Web of Science - 4
1997 OBrien PC, Franklin CI, Dear KBG, Hamilton CC, Poulsen M, Joseph DJ, et al., 'A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis', RADIOTHERAPY AND ONCOLOGY, 45 117-123 (1997)
DOI 10.1016/S0167-8140(97)00146-1
Citations Scopus - 71Web of Science - 57
1997 Smithers BM, Devitt P, Jamieson GG, Bessell J, Gotley D, Gill PG, et al., 'A combined modality approach to the management of oesophageal cancer', EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 23 219-223 (1997)
Citations Scopus - 20Web of Science - 18
1997 Simonen P, O'Brien M, Hamilton C, Ashcroft J, Denham J, 'Normal variation in cutaneous blood content and red blood cell velocity in humans', Physiological Measurement, 18 155-170 (1997)

This study was designed to determine normal variations in cutaneous blood content, red blood cell content and skin thickness in healthy human volunteers. The blood content (BC) of... [more]

This study was designed to determine normal variations in cutaneous blood content, red blood cell content and skin thickness in healthy human volunteers. The blood content (BC) of human skin and the velocity of red blood cells (RBV) has been comprehensively mapped over 30 anatomical sites in 28 volunteers between the age of 7 and 77 years using reflectance spectrophotometry (RFS) and laser Doppler (LD) techniques respectively. Total skin thickness, which may have a relationship with blood content, has been mapped at the same anatomical sites in six of the volunteers using two- dimensional array. 12 MHz ultrasound equipment. The major determinant of BC and RBV was found to be anatomical site. Regardless of age, gender or prior sun exposure, anatomical sites above the waist produced higher readings than below. BC and RBV were found to be dependent on age and gender at most sites with higher readings being observed in males and younger volunteers. The largest difference was seen in males under 55 years whose RFS readings above the waist were significantly higher than in older males or females of any age. Heavy prior sun exposure and skin thickness could not be demonstrated to impact on either RFS or LD readings independently of the effects of anatomical site, gender or age. In general, RFS and LD readings paralleled one another and correlated linearly at most anatomical sites. While RFS readings tended to decrease in the cranio-caudal direction, LD readings were relatively uniform across the body except for the head and groin where they were higher, and the abdomen where they were lower. The site-to-site variations in RFS readings observed in this study correspond well to capillary density variations noted in previous studies.

DOI 10.1088/0967-3334/18/3/001
Citations Scopus - 9
1996 Denham JW, Hamilton CS, Simpson SA, O'Brien M, 'Low dose rate teletherapy: Updated tumour response', Australasian Radiology, 40 155-157 (1996)

This report presents an update of tumour response experience in patients with locally advanced head and neck cancer treated on the low dose rate teletherapy project at the Mater M... [more]

This report presents an update of tumour response experience in patients with locally advanced head and neck cancer treated on the low dose rate teletherapy project at the Mater Misericordiae Hospital, Newcastle. Long-term progression-free survival figures are disappointing in all dose rate/total dose groupings and offer little encouragement that an improvement in therapeutic ratio can be achieved for head and neck cancer patients using teletherapy apparatus adjusted to treat at low and intermediate dose rates.

1996 MacKean J, Burmeister BH, Lamb DS, Denham JW, 'Concurrent chemoradiation for eosophageal cancer: Factors influencing myelotoxicity', Australasian Radiology, 40 424-429 (1996)

Concurrent chemotherapy and radiation (CT/RT) for localized oesophageal cancer can cause life-threatening myelosuppression. This non-randomized study examines 95 patients from thr... [more]

Concurrent chemotherapy and radiation (CT/RT) for localized oesophageal cancer can cause life-threatening myelosuppression. This non-randomized study examines 95 patients from three Australasian centres treated on the Trans-Tasman Radiation Oncology 'definitive' chemoradiation study. Duration of fluorouracil infusion and patient age were independently predictive of myelotoxicity after the first cycle of CT/RT. Overall rates of grade III and IV neutropaenia were 23% and of thrombocytopaenia 8% following the first cycle of chemotherapy. Five neutropaenic septic episodes followed the first cycle and six the second. All five patients recovered after the first cycle but there were four treatment-related deaths occurring after the second cycle of CT/RT. Recommendations are made concerning initial dosing, dose reductions and delays to minimize adverse patient outcomes from myelosuppression.

Citations Scopus - 12
1996 Lamb DS, Burmeister BH, Denham JW, 'Combined modality treatment for carcinoma oesophagus - Experience of the Trans-Tasman Radiation Oncology Group', BRITISH JOURNAL OF CANCER, 74 37-37 (1996)
1996 Ostwald PM, Kron T, Hamilton CS, Denham JW, 'Carbon-loaded LiF chips for in vivo skin dose assessment on patients undergoing radiotherapy', RADIATION PROTECTION DOSIMETRY, 66 319-322 (1996)
Citations Scopus - 2
1996 Kron T, Ostwald PM, Hamilton CS, Denham JW, 'TLD extrapolation measurements for entrance and exit dose in radiotherapy', RADIATION PROTECTION DOSIMETRY, 66 323-326 (1996)
Citations Scopus - 4Web of Science - 4
1996 Hamilton CS, Denham JW, OBrien M, Ostwald P, Kron T, Wright S, Dorr W, 'Underprediction of human skin erythema at low doses per fraction by the linear quadratic model', RADIOTHERAPY AND ONCOLOGY, 40 23-30 (1996)
DOI 10.1016/0167-8140(96)01764-1
Citations Scopus - 56Web of Science - 50
1996 Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS, et al., 'Factors influencing outcome following radio-chemotherapy for oesophageal cancer', RADIOTHERAPY AND ONCOLOGY, 40 31-43 (1996)
DOI 10.1016/0167-8140(96)01762-8
Citations Scopus - 42Web of Science - 40
1996 Denham JW, Walker QJ, Lamb DS, Hamilton CS, OBrien PC, Spry NA, et al., 'Mucosal regeneration during radiotherapy', RADIOTHERAPY AND ONCOLOGY, 41 109-118 (1996)
DOI 10.1016/S0167-8140(96)01830-0
Citations Scopus - 56Web of Science - 51
1996 Kron T, Butson M, Hunt F, Denham J, 'TLD extrapolation for skin dose determination in vivo', RADIOTHERAPY AND ONCOLOGY, 41 119-123 (1996)
DOI 10.1016/S0167-8140(96)01795-1
Citations Scopus - 32Web of Science - 28
1996 Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS, et al., 'Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)', Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 40 31-43 (1996)
1996 Denham JW, Walker QJ, Lamb DS, Hamilton CS, O'Brien PC, Spry NA, et al., 'Mucosal regeneration during radiotherapy. Trans Tasman Radiation Oncology Group (TROG).', Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 41 109-118 (1996)
1996 Howlett SJ, Denham JW, Kron T, 'Evaluation of rectal shielding in a Henschke system applicator', Strahlentherapie und Onkologie, 172 265-269 (1996)

Purpose: To assess the effectiveness of avoid shielding in the Henschke intracavitary gynaecologic 3-channel applicator. Material and methods: An acrylic phantom was used with our... [more]

Purpose: To assess the effectiveness of avoid shielding in the Henschke intracavitary gynaecologic 3-channel applicator. Material and methods: An acrylic phantom was used with our locally modified 3-channel Henschke applicator so that standard treatments with caesium-137 sources could be simulated. Thermoluminescent dosimeters were used to measure point A and rectal doses with and without ovoid shielding to assess the benefits of this shielding. Unshielded measurements were also compared to our planning computer calculations to assess its accuracy. The thermoluminescent dosimeters were calibrated against a caesium teletherapy unit. An estimate of shielding effect produced by the ovoid shielding when using iridium-192 wire was also determined. Results: Doses received at points in the plane containing the rectal point as defined by the ICRU in its report 38 show a reduction ranging from 5% to 15% over the area measured due to the ovoid shielding. As expected this benefit is more pronounced when using iridium-192 sources. Given the steep dose gradients, good agreement is found between computed and measured values of point A doses. Conclusion: While ovoid shielding will never provide a large reduction in rectal dose using caesium-137 sources, our results indicate that it can be a worthwhile option when using the Henschke applicator.

Citations Scopus - 3
1996 Denham JW, Hamilton CS, OBrien P, 'Regarding actuarial late effect analyses', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 35 197-197 (1996)
Citations Web of Science - 3
1996 Denham JW, Hamilton CS, O'Brien P, Caplan RJ, Pajak TF, Cox JD, 'Regarding actuarial late effect analyses: Bentzen et al., IJROBP 32:1531- 1534; 1995 and Caplan et al., IJROBP 32:1547; 1995 [1]', International Journal of Radiation Oncology Biology Physics, 35 197 (1996)
Citations Scopus - 5
1996 Denham JW, Denham E, Dear KB, Hudson GV, 'The follicular non-Hodgkin's lymphomas .1. The possibility of cure', EUROPEAN JOURNAL OF CANCER, 32A 470-479 (1996)
DOI 10.1016/0959-8049(95)00607-9
Citations Scopus - 35Web of Science - 33
1996 Denham JW, Denham E, Dear KB, Hudson GV, 'The follicular non-Hodgkin's lymphomas .2. Prognostic factors: What do they mean?', EUROPEAN JOURNAL OF CANCER, 32A 480-490 (1996)
DOI 10.1016/0959-8049(95)00635-4
Citations Scopus - 19Web of Science - 16
1996 Christie DRH, OBrien MY, Christie JA, Kron T, Ferguson SA, Hamilton CS, Denham JW, 'A comparison of methods of cosmetic assessment in breast conservation treatment', BREAST, 5 358-367 (1996)
DOI 10.1016/S0960-9776(96)90004-1
Citations Scopus - 38Web of Science - 32
1995 DENHAM JW, HAMILTON CS, CHRISTIE D, OBRIEN M, BONAVENTURA A, STEWART JF, et al., 'SIMULTANEOUS ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - TOXICITY AND DOSE MODIFICATION - A TRANS-TASMAN RADIATION ONCOLOGY GROUP MULTI-INSTITUTION STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 31 305-313 (1995)
DOI 10.1016/0360-3016(94)E0065-R
Citations Scopus - 28Web of Science - 23
Co-authors Stephen Ackland
1995 BURMEISTER BH, DENHAM JW, OBRIEN M, JAMIESON GG, GILL PG, DEVITT P, et al., 'COMBINED-MODALITY THERAPY FOR ESOPHAGEAL-CARCINOMA - PRELIMINARY-RESULTS FROM A LARGE AUSTRALASIAN MULTICENTER STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32 997-1006 (1995)
DOI 10.1016/0360-3016(94)00449-U
Citations Scopus - 51Web of Science - 44
Co-authors Stephen Ackland
1995 OSTWALD PM, KRON T, HAMILTON CS, DENHAM JW, 'CLINICAL USE OF CARBON-LOADED THERMOLUMINESCENT DOSIMETERS FOR SKIN DOSE DETERMINATION', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 33 943-950 (1995)
DOI 10.1016/0360-3016(95)00274-4
Citations Scopus - 17Web of Science - 12
Co-authors Patricia Ostwald
1995 Ferguson S, Ostwald P, Kron T, Denham J, 'Verification of surface dose on patients undergoing low to medium energy X-ray therapy', Medical Dosimetry, 20 161-165 (1995)

About 5% of patients still undergo cancer treatment with superficial (peak energy = 120 kVp) X-ray radiation. Dosimetry of these beams is difficult since the maximum dose is deliv... [more]

About 5% of patients still undergo cancer treatment with superficial (peak energy = 120 kVp) X-ray radiation. Dosimetry of these beams is difficult since the maximum dose is delivered at the surface and backscatter contributes significantly to the dose. This is particularly a problem in the difficult geometries encountered in superficial treatments in the head and neck area. It has recently been shown that surface dose measurements in mega-voltage X-ray beams can be performed using TLD (Thermoluminescence Dosimetry) extrapolation. In this technique, LiF TLD chips with a surface area of 3.15 × 3.15 cm2 and three different thicknesses (0.230, 0.099, and 0.038 g/cm2) are used together in the same radiation beam which allows the extrapolation of the measured dose back to the true surface. The energy response curve of the three thicknesses of LiF chips was measured for the energy range of 60kVp, HVL 1.6 mm Al to 300kVp, 4 mm Cu. LiF was found to over respond by a factor of 1.7 at 60kVp HVL 1.6 mm Al with respect to a 6MV photon beam. A feasibility study was carried out on three patients undergoing treatment at 120kVp. Because of the small field sizes involved it was necessary to limit irradiation to one or two chips at a time. The dose fall off in the first millimetre of tissue could be clearly detected. TLD extrapolation, in low to medium energy beams, was found to be useful to assess the dose of patients undergoing treatment for superficial lesions. © 1995.

DOI 10.1016/0958-3947(95)00009-L
Citations Scopus - 9
1995 Denham JW, 'How do we bring an acceptable level of radiotherapy services to a dispersed population?', Australasian Radiology, 39 171-173 (1995)

Radiotherapy referral data from four Australian States confirm that access difficulties contribute to low radiotherapy utilization rates. Access could be improved by the provision... [more]

Radiotherapy referral data from four Australian States confirm that access difficulties contribute to low radiotherapy utilization rates. Access could be improved by the provision of further small treatment centres in moderately large rural or semi-rural population centres. Such a policy, however, could endanger existing standards of radiotherapeutic care unless the potential pitfalls of such an approach are addressed prospectively.

Citations Scopus - 38
1995 DENHAM JW, HAMILTON CS, SIMPSON SA, OBRIEN MY, OSTWALD PM, KRON T, DEAR KBG, 'ACUTE REACTION PARAMETERS FOR HUMAN OROPHARYNGEAL MUCOSA', RADIOTHERAPY AND ONCOLOGY, 35 129-137 (1995)
DOI 10.1016/0167-8140(95)01545-R
Citations Scopus - 28Web of Science - 27
Co-authors Patricia Ostwald
1995 DENHAM JW, HAMILTON CS, SIMPSON SA, OSTWALD PM, OBRIEN M, KRON T, et al., 'FACTORS INFLUENCING THE DEGREE OF ERYTHEMATOUS SKIN REACTIONS IN HUMANS', RADIOTHERAPY AND ONCOLOGY, 36 107-120 (1995)
DOI 10.1016/0167-8140(95)01599-C
Citations Scopus - 28Web of Science - 28
Co-authors Patricia Ostwald
1994 Hamilton CS, Denham JW, 'Low dose rate teletherapy and tumour response [1]', Australasian Radiology, 38 85 (1994)
1994 Denham JW, Dobbs HJ, Hamilton CS, 'ICRU 50: A commentary', Australasian Radiology, 38 204-207 (1994)
Citations Scopus - 1
1994 DENHAM JW, HAMILTON CS, 'RESOURCE RESTRAINTS - WHAT DO WE TELL OUR PATIENTS', MEDICAL JOURNAL OF AUSTRALIA, 160 95-96 (1994)
1994 DENHAM JW, 'ESOPHAGEAL CANCER - GUARDED OPTIMISM', MEDICAL JOURNAL OF AUSTRALIA, 160 669-670 (1994)
Citations Web of Science - 1
1994 DENHAM JW, HAMILTON CS, OBRIEN PC, 'WOMEN WHO DEVELOP BREAST-CANCER', MEDICAL JOURNAL OF AUSTRALIA, 161 507-507 (1994)
1994 OSTWALD PM, COOPER SG, DENHAM JW, HAMILTON CS, 'DOSIMETRY OF HIGH-ENERGY ELECTRON THERAPY TO THE PAROTID REGION', RADIOTHERAPY AND ONCOLOGY, 33 148-156 (1994)
DOI 10.1016/0167-8140(94)90069-8
Citations Scopus - 6Web of Science - 3
Co-authors Patricia Ostwald
1994 OSTWALD PM, METCALFE PE, DENHAM JW, HAMILTON CS, 'A COMPARISON OF 3 ELECTRON PLANNING-ALGORITHMS FOR A 16 MEV ELECTRON-BEAM', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 28 731-740 (1994)
Citations Scopus - 7Web of Science - 6
Co-authors Patricia Ostwald
1993 Hamilton CS, Simpson SA, Ferguson S, Ostwald P, Hsu W, O'Brien M, Denham JW, 'Low dose teletherapy and tumour response', Australasian Radiology, 37 210-212 (1993)

Tumour responses in 25 patients with locally advanced head and neck cancer, treated on an experimental fractionated low dose rate (FLDR) teletherapy program are reported. Treatmen... [more]

Tumour responses in 25 patients with locally advanced head and neck cancer, treated on an experimental fractionated low dose rate (FLDR) teletherapy program are reported. Treatment was given at dose rates ranging from 1.8 to 3 Gy/h to a range of total doses from 32-38 Gy, with palliative intent. The total doses delivered have been predicted by the linear quadratic formula to be equivalent to 33-41 Gy using conventionally fractionated high dose rate treatment, in terms of acute normal tissue effects. a complete response rate (no visible or palpable disease 2 months after treatment) was observed in 28% of cases. Analysis of these response rates suggests that the linear quadratic formula may underestimate the anti-tumour effect of FLDR teletherapy at the various dose rates and total dose permutations in this study.

Citations Scopus - 4
1993 Denham JW, Hamilton CS, Joseph DJ, Lamb DS, Spry NA, Gray AJ, et al., 'The use of simulator and CT information in the planning of radiotherapy for non-small cell lung cancer: An Australasian patterns of practice study', Lung Cancer, 8 275-284 (1993)

In a patterns of practice study 14 Australasian radiation oncologists were invited to define tumour and target volumes in 12 sample cases of non-small cell carcinoma of the lung (... [more]

In a patterns of practice study 14 Australasian radiation oncologists were invited to define tumour and target volumes in 12 sample cases of non-small cell carcinoma of the lung (NSCCL) firstly using orthogonal simulator AP and lateral radiographic views, then using computed tomography (CT) slices obtained in the treatment position. In addition, they were asked to complete questionnaires addressing their criteria for determining treatment policy and their reasons for choosing specific tumour and target volume boundaries in individual cases. Significant variations in choice of size and position of both tumour and target volume were apparent between clinicians. These variations, however were no greater for simulator planned volumes than for CT planned volumes, except in cases selected for palliative treatment, were CT planned volumes were significantly larger. Failure to include tumour extensions, the mistaken inclusion of normal structures as tumour, and major differences in allowance for microscopic tumour spread were identified as the most significant cause for variation in the size and positioning of target volumes between clinicians. Differences over margins to allow for factors such as variation in day-to-day set-up, patient movement, equipment-related factors, etc, were also apparent. CT and simulator planned target volumes were equally successful in adequate tumour coverage; 79 162 (49%), and 80 162 (49%) respectively. Gross miss of tumour was more common in simulator planned target volumes than CT planned target volumes; 70 162 (43%) and 55 162 (34%), respectively. This study supports the integration of diagnostic expertise into the planning process for simulator and CT planning, but suggests that substantial practice variation would still exist in planning for radiotherapy in NSCCL. © 1993.

DOI 10.1016/0169-5002(93)90476-E
Citations Scopus - 3
1993 DENHAM JW, DALLY MJ, HUNTER K, WHEAT J, FAHEY PP, HAMILTON CS, 'OBJECTIVE DECISION-MAKING FOLLOWING A PORTAL FILM - THE RESULTS OF A PILOT-STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 26 869-876 (1993)
Citations Scopus - 55Web of Science - 46
1993 Ackland SP, Hamilton CS, Joseph DJ, Denham JW, 'Phase I/II study of concurrent weekly carboplatin and radiation therapy in advanced head and neck cancer', Clinical Oncology, 5 133-138 (1993)

Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 day... [more]

Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 days/week to a total dose of 64-70 Gy over 7-8 weeks) in a Phase I/II study. Carboplatin was administered weekly during RT at doses of 75-150 mg/m2//wk as a 1-hour infusion. The maximum tolerated dose of carboplatin was 130 mg/m2//wk, with myelosuppression, predominantly neutropenia, being dose limiting. Other systemic toxicities were insignificant and no overlapping toxicity was evident. Ultimate locoregional control and survival probabilities were disappointing. It is suggested that either further studies using radiation and carboplatin at the dose 130 mg/m2//wk, or variations on dose and scheduling be performed prior to the instigation of Phase III studies. © 1993 The Royal College of Radiologists.

DOI 10.1016/S0936-6555(05)80307-3
Citations Scopus - 4
Co-authors Stephen Ackland
1993 Cooper SG, Bonaventura A, Ackland SP, Joseph DJ, Stewart JF, Hamilton CS, Denham JW, 'Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: A phase II study', Clinical Oncology, 5 169-173 (1993)

Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival. We wished to find out if we could safely give concurrent ra... [more]

Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival. We wished to find out if we could safely give concurrent radiotherapy and 5-fluorouracil (5-FU) modulated by leucovorin (LV) in 3 settings: pre-operatively, adjuvantly and in recurrent disease. A total of 39 patients were treated, 11 preoper-atively, 17 adjuvantly and 11 with recurrent disease. There were 26 males and 13 females with a median age of 64 years. The median radiotherapy (RT) dose was 45 Gy/25 fractions/1.8 Gy per fraction (range 25-63 Gy). Chemotherapy consisted of LV 80 mg/m2 i.v. infusion over 1.5 hours followed by 5-FU 400 mg/m2 i.v. bolus, both given once a week. The median number of cycles was 8 (range 3-12). Diarrhoea was the main toxicity, and was encountered in 30 patients (77%): grade 1 in 3 (8%), grade 2 in 12 (30%), grade 3 in 11 (28%), and grade 4 in 4 (10%). This required 18 (46%) patients to have modifications to their RT (20% had breaks and 26% ceased at doses <45 Gy). Nine patients (23%) had modifications in the chemotherapy (10% had breaks and 13% received <6 cycles). Encouraging responses were seen in the preoperative setting. Concurrent RT and 5-FU/LV, as given in this schedule, results in an unacceptable incidence of diarrhoea, limiting both the total dose of RT and chemotherapy that can be delivered, particulary in patients who have had previous surgery. © 1993 The Royal College of Radiologists.

DOI 10.1016/S0936-6555(05)80319-X
Citations Scopus - 12
Co-authors Stephen Ackland
1992 GILL PG, DENHAM JW, JAMIESON GG, DEVITT PG, YEOH E, OLWENY C, 'PATTERNS OF TREATMENT FAILURE AND PROGNOSTIC FACTORS ASSOCIATED WITH THE TREATMENT OF ESOPHAGEAL-CARCINOMA WITH CHEMOTHERAPY AND RADIOTHERAPY EITHER AS SOLE TREATMENT OR FOLLOWED BY SURGERY', JOURNAL OF CLINICAL ONCOLOGY, 10 1037-1043 (1992)
Citations Web of Science - 90
1992 Hamilton CS, Denham JW, 'Dose normalisation and specification: From woe to go', Australasian Radiology, 36 137-141 (1992)
Citations Scopus - 1
1992 DENHAM JW, 'IMPLANTATION OF THE TONGUE AND FLOOR OF MOUTH - WHAT FACTORS REALLY DO CONTRIBUTE TO NECROSIS', RADIOTHERAPY AND ONCOLOGY, 24 64-65 (1992)
DOI 10.1016/0167-8140(92)90356-Y
1992 HAMILTON CS, CHAN LY, MCELWAIN DLS, DENHAM JW, 'A PRACTICAL EVALUATION OF 5-DOSE-VOLUME HISTOGRAM REDUCTION ALGORITHMS', RADIOTHERAPY AND ONCOLOGY, 24 251-260 (1992)
DOI 10.1016/0167-8140(92)90232-J
Citations Scopus - 14Web of Science - 13
1992 CROSS P, JOSEPH DJ, CANT J, COOPER SG, DENHAM JW, 'TANGENTIAL BREAST IRRADIATION - SIMPLE IMPROVEMENTS', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 23 433-442 (1992)
Citations Scopus - 18Web of Science - 11
1992 Hamilton CS, Denham JW, Joseph DJ, Lamb DS, Spry NA, Gray AJ, et al., 'Treatment and planning decisions in non-small cell carcinoma of the lung: An Australasian patterns of practice study', Clinical Oncology, 4 141-147 (1992)

Fourteen practising radiation oncologists were surveyed to assess their treatment and planning habits utilizing six sample cases of non-small cell carcinoma of the lung. Responden... [more]

Fourteen practising radiation oncologists were surveyed to assess their treatment and planning habits utilizing six sample cases of non-small cell carcinoma of the lung. Respondents were first given a general questionnaire, designed to evaluate their theoretical treatment and planning recommendations based on various tumour and patient related variables. Respondents then undertook a practical planning exercise utilizing planning CT and simulator radiographs for each of the six sample cases. Each case was accompanied by a brief history and report outlining specific tumour stage and non-stage related variables. The practical planning exercise was repeated on the second day of the survey utilizing different non-stage related variables but identical radiology and stage-related information. This design enabled firstly, a comparison of clinicians' intended policy and planning methods with actual policy and planning decisions, and secondly, an assessment of intra-clinician variability in decision making and planning practice. Good agreement was evident among clinicians with respect to general, non-case specific treatment policies; however, very significant variation occurred at an inter- and intra-clinician level and involved the entire treatment and planning process for individual cases. Despite identical treatment intent across identical radiological case pairings, clinicians chose widely differing margins and target volumnes in their planning exercise. Treatment intent appeared to be influenced more by non-stage related variables rather than stage related information and radiological appearances per se. We have shown that experienced radiation oncologists do not adhere to stated case selection criteria and show inconsistencies in their treatment planning for non-small cell carcinoma of the lung. © 1992 The Royal College of Radiologists.

DOI 10.1016/S0936-6555(05)81075-1
Citations Scopus - 26
1991 DENHAM JW, ABBOTT RL, 'CONCURRENT CISPLATIN, INFUSIONAL FLUOROURACIL, AND CONVENTIONALLY FRACTIONATED RADIATION-THERAPY IN HEAD AND NECK-CANCER - DOSE-LIMITING MUCOSAL TOXICITY', JOURNAL OF CLINICAL ONCOLOGY, 9 458-463 (1991)
Citations Scopus - 25Web of Science - 25
1991 Hamilton CS, Piyaratna N, Ferguson SA, Callaghan TM, Denham JW, 'Clinical utility of high-resolution portal films', Clinical Oncology, 3 90-95 (1991)

We have evaluated the film quality and overall clinical utility of a unique high-resolution portal film system which utilizes high contrast graphics art film. A total of 127 unsel... [more]

We have evaluated the film quality and overall clinical utility of a unique high-resolution portal film system which utilizes high contrast graphics art film. A total of 127 unselected patients had their conventional portal films and high-resolution films of the same site, compared and graded subjectively for a variety of parameters by an independent panel of radiotherapists and radiographers. Although consistent improvements in most aspects of image quality were noted, improved overall clinical usefulness of the high-resolution portal film system in comparison to the conventional films, when subjected to multiple regression analysis, was confined to lateral neck views only. High-resolution portal film utility was also found to depend significantly on field size with areas less than 110 cm2 having a markedly worse clinical utility score. © 1991 The Royal College of Radiologists.

Citations Scopus - 3
1991 Denham JW, Hamilton CS, Cross P, 'Breast conservation, the problem of treating the excision site effectively: Physical criteria for the choice of technique used', Clinical Oncology, 3 250-256 (1991)

This paper examines how physical factors such as the depth of the excision cavity below the skin surface and its distance from the underlying lung may impact upon the choice betwe... [more]

This paper examines how physical factors such as the depth of the excision cavity below the skin surface and its distance from the underlying lung may impact upon the choice between the use of an electron field (from a Varian Clinac 1800) or an implant (using a double plane of iridium-192 wires). Data have been derived from a phantom dosimetry experiment simulating different permutations of breast size and depth of excision cavity. An anthropomorphic female phantom with two different-sized wax breast phantoms has been used to simulate the clinical circumstances envisaged and iso-dose distributions have been estimated from an array of TLD readings. The biological significance of doses measured in skin and lung have been examined using the linear-quadratic (LQ) model. Both on physical and biological grounds, the results favour the implant under the experimental conditions adopted. The use of the electron beam to definitively treat the excision cavity (omitting breast tangents) to 60 Gy would result in unacceptable late effects in the skin and an observable incidence of pneumonitis if the excision cavity were near the chest wall. Small carcinogenic risks, particularly to the lung, are apparent with each modality, but may be moderated for the iridium-192 implant by a reduced carcinogenic potential associated with low-dose rate radiation. The use of the newer radionuclides iodine-125 and samarium-145, with less penetrating gamma ray emissions, might be preferred to iridium-192 from the point of view of bronchial carcinogenesis if definitive treatment of the exision cavity became widespread practice. © 1991 The Royal College of Radiologists.

DOI 10.1016/S0936-6555(05)80872-6
Citations Scopus - 9
1991 Denham JW, Sillar RW, Clarke D, 'Boost dosage to the excision site following conservative surgery for breast cancer: It's easy to miss!', Clinical Oncology, 3 257-261 (1991)

Surgical haemoclips have been left in situ in 27 consecutive patients conservatively operated on for early breast cancer by two surgeons in Newcastle, New South Wales, to demarcat... [more]

Surgical haemoclips have been left in situ in 27 consecutive patients conservatively operated on for early breast cancer by two surgeons in Newcastle, New South Wales, to demarcate the limits of the excision cavity for accurate postoperative irradiation. As anticipated, the position of these clips varied widely in relation to the patient's recollection of the position of the original lump, the surgical notes, and the surgical scar. In addition the dimensions of the clipped area also varied considerably. So great was the variation in position of the clips that incomplete coverage of the excision cavity in the 'coronal' (en face) plane using an electron field could have occurred in an estimated 10/24 (42%) evaluable cases had surgical clips not been left in situ. Depth of the surgical clips below the skin surface also varied markedly between patients. In 9/26 (73%) evaluable cases the clips were observed to be sited 3 cm or more below the skin surface, while in only 5/26 (19.2%) were the clips found to be 2 cm or less deep to the surface. Had a 9 MeV beam from our Clinac 1800 been used to treat all the cases, a major underdose of the excision cavity would have been likely in 21/26 (81%) evaluable cases. This figure would be improved to 11/26 (42%) had a 12 MeV beam been used - still a very high figure. Neither of these points have received much attention in the literature. This small study sounds a distinct warning and needs to be repeated on a larger scale. © 1991 The Royal College of Radiologists.

DOI 10.1016/S0936-6555(05)80873-8
Citations Scopus - 41
1991 Hamilton CS, Piyaratna N, Ferguson SA, Callaghan TM, Denham JW, 'Clinical utility of high-resolution portal films.', Clinical oncology (Royal College of Radiologists (Great Britain)), 3 90-95 (1991)
1990 GILL PG, JAMIESON GG, DENHAM J, DEVITT PG, AHMAD A, YEOH E, JONES AM, 'TREATMENT OF ADENOCARCINOMA OF THE CARDIA WITH SYNCHRONOUS CHEMOTHERAPY AND RADIOTHERAPY', BRITISH JOURNAL OF SURGERY, 77 1020-1023 (1990)
DOI 10.1002/bjs.1800770922
Citations Web of Science - 37
1990 Hamilton CS, Denham JW, 'The cure of primary prostate cancer by radiotherapy - High-tech quest for a non-existent grail?', Australasian Radiology, 34 5-11 (1990)
1990 Cooper SG, Cardew AP, Ferguson S, Joseph DJ, Hamilton CS, Denham JW, 'Low dose rate teletherapy using a telecaesium 137 unit: Radiobiological, physical and clinical considerations', Australasian Radiology, 34 241-246 (1990)
Citations Scopus - 5
1990 Hamilton CS, Joseph DJ, Skov A, Denham JW, 'CT scanning for definitive radiotherapy planning of prostate cancer: necessity or nicety? Results from survey of radiation oncologists working at different institutions in Australia', Australasian Radiology, 34 288-292 (1990)
Citations Scopus - 6
1990 COOPER SG, DENHAM JW, 'PROGRESSIVE SYSTEMIC-SCLEROSIS (DIFFUSE SCLERODERMA) AND RADIOTHERAPY', BRITISH JOURNAL OF RADIOLOGY, 63 804-805 (1990)
Citations Scopus - 21Web of Science - 17
1990 JOSEPH DJ, HAMILTON CS, DENHAM JW, ACKLAND SP, STEWART JF, 'WHITHER SCREENING MAMMOGRAPHY IN AUSTRALIA - ESTABLISHING A SATISFACTORY BASIS FOR FUNDING', MEDICAL JOURNAL OF AUSTRALIA, 152 545-546 (1990)
Co-authors Stephen Ackland
1990 FENECH M, DENHAM J, FRANCIS W, MORLEY A, 'MICRONUCLEI IN CYTOKINESIS-BLOCKED LYMPHOCYTES OF CANCER-PATIENTS FOLLOWING FRACTIONATED PARTIAL-BODY RADIOTHERAPY', INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 57 373-383 (1990)
DOI 10.1080/09553009014552471
Citations Scopus - 95Web of Science - 104
1989 REECE PA, STAFFORD I, ABBOTT RL, ANDERSON C, DENHAM J, FREEMAN S, et al., '2-HOUR VERSUS 24-HOUR INFUSION OF CISPLATIN - PHARMACOKINETIC CONSIDERATIONS', JOURNAL OF CLINICAL ONCOLOGY, 7 270-275 (1989)
Citations Web of Science - 48
1989 COOPER SG, DENHAM JW, HAMILTON CS, JOSEPH DJ, STEWART JF, ACKLAND SP, 'THE PRICE OF A FALSE-NEGATIVE RESULT OF MAMMOGRAPHY AND AN OVERENTHUSIASTIC LAY PRESS', MEDICAL JOURNAL OF AUSTRALIA, 150 664-664 (1989)
Citations Web of Science - 1
Co-authors Stephen Ackland
1988 DENHAM JW, GILL PG, JAMIESON GG, HETZEL D, DEVITT P, FITCH R, et al., 'PRELIMINARY EXPERIENCE WITH A COMBINED-MODALITY APPROACH TO THE MANAGEMENT OF ESOPHAGEAL CANCER', MEDICAL JOURNAL OF AUSTRALIA, 148 9-13 (1988)
Citations Web of Science - 13
1988 DENHAM JW, BALDACCHINO AC, GUTTE J, NICHOLLS RL, 'REMOTE AFTERLOADING TECHNIQUES FOR THE TREATMENT OF NASOPHARYNGEAL AND ENDOMETRIAL CANCER', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 14 191-195 (1988)
Citations Web of Science - 6
1988 DENHAM JW, CARTER ML, GILL PG, 'CONSERVATIVE TREATMENT OF BREAST-CANCER - WHERE SHOULD THE BOOSTER DOSE GO', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 14 399-400 (1988)
Citations Web of Science - 23
1988 DENHAM JW, 'SYNCHRONOUS RADIATION AND CHEMOTHERAPY - REPLY', MEDICAL JOURNAL OF AUSTRALIA, 148 370-370 (1988)
1987 OBRIEN PC, DENHAM JW, LEONG ASY, 'MERKEL CELL-CARCINOMA - A REVIEW OF BEHAVIOR PATTERNS AND MANAGEMENT STRATEGIES', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 57 847-850 (1987)
DOI 10.1111/j.1445-2197.1987.tb01278.x
Citations Web of Science - 14
1987 DENHAM JW, ABBOTT RL, GILL PG, 'SYNCHRONOUS RADIATION AND CHEMOTHERAPY IN CARCINOMA OF THE UPPER AERODIGESTIVE TRACTS', MEDICAL AND PEDIATRIC ONCOLOGY, 15 135-135 (1987)
1987 DENHAM JW, YEOH EK, WITTWER G, WARD GG, AHMAD AS, HARVEY NDM, 'RADIATION-THERAPY IN HYPERBARIC-OXYGEN FOR HEAD AND NECK-CANCER AT ROYAL ADELAIDE HOSPITAL - 1964 TO 1980', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 13 201-208 (1987)
Citations Web of Science - 12
1987 DENHAM JW, 'SYNCHRONOUS RADIATION AND CHEMOTHERAPY FOR LOCALLY-ADVANCED CANCER - IS IT THE ANSWER .1.', MEDICAL JOURNAL OF AUSTRALIA, 147 590-595 (1987)
Citations Web of Science - 5
1986 DENHAM JW, CARTER ML, 'THE SELECTION OF CASES FOR WEDGE EXCISION FOLLOWED BY RADIOTHERAPY AS THE TREATMENT OF THEIR PRIMARY BREAST-CANCER', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 56 5-12 (1986)
DOI 10.1111/j.1445-2197.1986.tb01811.x
1986 DENHAM JW, CARTER ML, 'LOCATION OF THE EXCISION SITE FOLLOWING SEGMENTAL-MASTECTOMY FOR ACCURATE POSTOPERATIVE IRRADIATION', AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 56 685-688 (1986)
DOI 10.1111/j.1445-2197.1986.tb02373.x
Citations Web of Science - 10
1986 DENHAM JW, 'THE RADIATION DOSE-RESPONSE RELATIONSHIP FOR CONTROL OF PRIMARY BREAST-CANCER', RADIOTHERAPY AND ONCOLOGY, 7 107-123 (1986)
DOI 10.1016/S0167-8140(86)80090-1
Citations Web of Science - 26
1986 YEOH EK, DENHAM JW, DAVIES SA, SPITTLE MF, 'PRIMARY BREAST-CANCER - COMPLICATIONS OF AXILLARY MANAGEMENT', ACTA RADIOLOGICA ONCOLOGY, 25 105-108 (1986)
Citations Web of Science - 48
1986 Yeoh EK, Denham JW, Davies SA, Spittle MF, 'Primary breast cancer. Complications of axillary management', Acta Radiologica Oncology, 25 105-108 (1986)

The complications following surgery and postoperative radiation therapy in the management of the axilla in 187 patients with primary breast cancer treated between 1978 and 1982 ha... [more]

The complications following surgery and postoperative radiation therapy in the management of the axilla in 187 patients with primary breast cancer treated between 1978 and 1982 have been studied. Although no difference in complication rate could be detected between the three different postoperative radiation schedules utilised there was a strong and positive correlation between complication rate and increasing extent of surgical intervention. When the groups were sub-divided according to the extent of surgery performed, no differences in regional recurrence rates were observed but complication rates (defined as significant lymphoedema of the arm and/or restriction of shoulder movements) were significantly different (p<0.001) at 30 months between those who had no surgical intervention (25%), those who had had 'sampling' performed (50%) and those who had had formal dissection performed (84%).

Citations Scopus - 63
1985 HUDSON FR, DENHAM JW, 'THE COMPUTER-ANALYSIS OF INTERSTITIAL IMPLANTS IN RADIOTHERAPY', RADIOTHERAPY AND ONCOLOGY, 4 175-184 (1985)
DOI 10.1016/S0167-8140(85)80105-5
1984 DENHAM JW, STRICKLAND P, 'RECENT EXPERIENCE IN THE RADICAL IRRADIATION OF PRIMARY BREAST-CANCER AT MOUNT-VERNON-HOSPITAL', EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 20 189-& (1984)
DOI 10.1016/0277-5379(84)90183-4
Citations Scopus - 3Web of Science - 4
1984 DENHAM JW, MACLENNAN KA, 'THE MANAGEMENT OF PRIMARY-CARCINOMA OF THE FALLOPIAN-TUBE - EXPERIENCE OF 40 CASES', CANCER, 53 166-172 (1984)
DOI 10.1002/1097-0142(19840101)53:1<166::AID-CNCR2820530129>3.0.CO;2-B
Citations Scopus - 48Web of Science - 56
1983 DENHAM JW, HUDSON FR, 'IRIDIUM AFTERLOADING TECHNIQUES', BRITISH JOURNAL OF RADIOLOGY, 56 780-781 (1983)
1983 HUDSON FR, DENHAM JW, 'NEEDLE AFTERLOADING TECHNIQUES', BRITISH JOURNAL OF RADIOLOGY, 56 781-781 (1983)
1982 Denham JW, Strickland P, Alderson AM, Hudson FR, Bennett MH, 'Interstitial radiation therapeutic techniques at mount Vernon hospital', Acta Oncologica, 21 385-392 (1982)

Retrospective analysis of 56 cases of carcinoma on the lateral border of the anterior two thirds of the tongue treated at Mount Vernon Hospital using radium needle implant alone y... [more]

Retrospective analysis of 56 cases of carcinoma on the lateral border of the anterior two thirds of the tongue treated at Mount Vernon Hospital using radium needle implant alone yielded 5-year actuarial survivals of 75.3 per cent in 25 T1NO cases and 81.8 per cent in 25 T2NO cases. Five-year actuarial local recurrence of 17.5 per cent was recorded in the T1 group and 35 per cent in the T2 group. Local recurrences were attributed to failure of the implant to encompass extensions of the tumour along the lateral border or into the musculature of the tongue. Five-year actuarial local recurrence of 66.2 per cent was recorded in 18 patients with carcinoma of the breast treated by radium needle implant alone; 4 of these 9 local recurrences occurred at some distance from the treated area and could not be classed as marginal recurrences. A preliminary investigation carried out in 1981 indicated that significant improvements in source distribution, particularly at poorly accessible sites, could be achieved using afterloading techniques. In addition the use of 192Ir as a source could result in improvements in staff protection. ©1982 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

DOI 10.3109/02841868209134317
Citations Scopus - 1
1982 DENHAM JW, 'A CASE OF THERMALLY INDUCED CANCER', CLINICAL ONCOLOGY, 8 357-360 (1982)
Citations Web of Science - 1
1982 DENHAM JW, STRICKLAND P, ALDERSON AM, HUDSON FR, BENNETT MH, 'INTERSTITIAL RADIATION THERAPEUTIC TECHNIQUES AT MOUNT-VERNON-HOSPITAL', ACTA RADIOLOGICA ONCOLOGY, 21 385-392 (1982)
Citations Web of Science - 2
Show 206 more journal articles

Conference (61 outputs)

Year Citation Altmetrics Link
2015 Warren LE, Chen M-H, Denham JW, Steigler A, Renshaw AA, Loffredo MJ, et al., 'Gleason grade 5 and the risk of death from prostate cancer following radiation with or without 6 months of conventional androgen deprivation therapy.', JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Allison Steigler
2014 Carter G, Clover KA, Britton B, Mitchell AJ, White M, McLeod N, et al., 'WELLBEING DURING ACTIVE SURVEILLANCE FOR LOCALISED PROSTATE CANCER: A SYSTEMATIC REVIEW OF PSYCHOLOGICAL MORBIDITY AND QUALITY OF LIFE', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Gregory Carter
2014 Denham JW, Joseph DJ, Lamb DS, Spry N, Duchesne GM, Matthews J, et al., 'Main oncologic endpoints of the TROG 03.04 (RADAR) Trial for men with locally advanced prostate cancer', JOURNAL OF CLINICAL ONCOLOGY (2014)
Citations Web of Science - 1
Co-authors Allison Steigler, John Attia
2014 Ebert MA, Foo K, Haworth A, Gulliford SL, Kearvall R, Kennedy A, et al., 'Derivation and representation of dose-volume response from large clinical trial data sets: An example from the RADAR prostate radiotherapy trial', Journal of Physics: Conference Series (2014) [E1]

Large multicentre radiotherapy trials incorporating assessment of multiple outcomes at multiple timepoints can generate extensive datasets. We have investigated graphical techniqu... [more]

Large multicentre radiotherapy trials incorporating assessment of multiple outcomes at multiple timepoints can generate extensive datasets. We have investigated graphical techniques for presentation of this data and the associated underlying dose-volume response information, necessary for guiding statistical analyses and translating outcomes to future patient treatments. A relational database was used to archive reviewed plan data for patients accrued to the TROG 03.04 RADAR trial. Viewing software was used to clean and enhance the data. Scripts were developed to export arbitrary dose-histogram data which was combined with clinical toxicity data with a median follow-up of 72 months. Graphical representations of dose-volume response developed include prevalence atlasing, univariate logistic regression and dose-volume-point odds ratios, and continuous cut-point derivation via ROC analysis. These representations indicate variable association of toxicities across structures and time-points. © Published under licence by IOP Publishing Ltd.

DOI 10.1088/1742-6596/489/1/012090
Citations Scopus - 1
2013 Denham J, Wilcox C, Sharpley C, 'Understanding "Survivorship" in prostate cancer: An investigation of predictors for "Loss of Masculinity" among RADAR participants', BJU INTERNATIONAL (2013) [E3]
2013 Galvao DA, Taaffe DR, Spry N, Denham J, Cormie P, Joseph D, et al., 'A MULTICENTER YEAR-LONG RANDOMIZED CONTROLLED TRIAL OF EXERCISE TRAINING TARGETING CARDIOVASCULAR RISK FACTORS AND PHYSICAL FUNCTIONING IN OLDER MEN WITH PROSTATE CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013) [E3]
2012 Galvao DA, Spry N, Taaffe DR, Denham J, Joseph D, Peddle-Mcintyre C, et al., 'Effects of exercise on cardiometabolic profile of prostate cancer survivors from radar: a Multicentre randomized trial', Supportive Care in Cancer: Abstracts of the 2012 International MASCC/ISOO Symposium (2012) [E3]
2012 Peddle-Mcintyre C, Newton RU, Spry N, Taaffe DR, Denham J, Joseph D, et al., 'A randomized trial of supervised exercise versus print materials on muscle strength and function in prostate cancer survivors from radar', Supportive Care in Cancer: Abstracts of the 2012 International MASCC/ISOO Symposium (2012) [E3]
2012 Denham J, 'Will the ill effects of treatment on the experimental arms of the radar trial for men with locally advanced prostate cancer be worth it?', Asia-Pacific Journal of Clinical Oncology (2012) [E3]
2011 Dowling JA, Fripp J, Chandra S, Pluim JPW, Lambert JA, Parker J, et al., 'Fast automatic multi-atlas segmentation of the prostate from 3D MR images', International Workshop on Prostate Cancer Imaging: Image Analysis and Image-Guided Interventions Proceedings (LNCS 6963) (2011) [E1]
DOI 10.1007/978-3-642-23944-1_2
Citations Scopus - 20Web of Science - 16
Co-authors Peter Greer
2011 Lambert JA, Dowling J, Menk FW, Parker J, Capp A, Denham J, et al., 'MR-based dose calculation for prostate radiotherapy using atlas-based auto-segmentation', Medical Physics (2011) [E3]
Co-authors Fred Menk, Peter Greer
2011 Denham J, Ball JI, Joseph DJ, Lamb DS, Duchesne GM, Diamond T, et al., 'Bone mineral density loss and fractures in the TROG 03.04 (RADAR) Trial', European Journal of Cancer (2011) [E3]
Citations Web of Science - 1
2011 Denham J, Steigler A, Lamb DS, Joseph DJ, Matthews J, Atkinson C, et al., 'Variations in androgen dependent clinical progression kinetics in locally advanced prostate cancer', European Journal of Cancer (2011) [E3]
Co-authors Allison Steigler, Catherine Deste
2010 Dowling J, Lambert JA, Parker J, Greer PB, Fripp J, Denham J, et al., 'Automatic MRI atlas-based external beam radiation therapy treatment planning for prostate cancer', Prostate Cancer Imaging: Computer-Aided Diagnosis, Prognosis, and Intervention International Workshop, Held in Conjunction with MICCAI 2010, Beijing,China, September 24, 2010. Proceedings (2010) [E1]
Citations Scopus - 10Web of Science - 8
Co-authors Peter Greer
2009 Gustafsson H, Vial P, Kuncic Z, Baldock C, Denham J, Greer PB, 'Intensity modulated radiation therapy verification with a novel modified EPID design', Journal of Medical Imaging and Radiation Oncology (2009) [E3]
Co-authors Peter Greer
2009 Dowling J, Neubert A, Fripp J, Bourgeat P, Patterson J, Denham J, et al., 'Atlas-based, automatic segmentation of the pelvis for prostate radiotherapy planning', Journal of Medical Imaging and Radiation Oncology (2009) [E3]
DOI 10.1111/j.1440-1673.2009.01207.x
Co-authors Peter Greer
2009 Ebert MA, Harrison KM, Howlett SJ, Cornes D, Kron T, Joseph DJ, et al., 'Outcomes of the 2004-2008 Australasian level III dosimetry intercomparison', Journal of Medical Imaging and Radiation Oncology (2009) [E3]
DOI 10.1111/j.1440-1673.2009.01207.x
2009 Ebert MA, Hooton B, Kearvell R, Haworth A, Spry NA, Bydder SA, et al., 'Collection of digital treatment planning data for radiotherapy trials: Progress in Australasia and internationally', Journal of Medical Imaging and Radiation Oncology (2009) [E3]
DOI 10.1111/j.1440-1673.2009.01207.x
2009 Dowling J, Bourgeat P, Raffelt D, Fripp J, Greer PB, Patterson J, et al., 'Non-rigid correction of interleaving artefacts in pelvic MRI', Medical Imaging 2009: Image Processing (2009) [E1]
DOI 10.1117/12.812460
Citations Scopus - 3
Co-authors Peter Stanwell, Peter Greer
2009 Baines SK, Moroney C, Bowe SJ, Denham J, Capra S, 'Investigating lifestyle behaviours of Australian survivors of prostate cancer', Proceedings of the Nutrition Society of Australia (2009) [E3]
Co-authors Surinder Baines
2007 Denham J, Joseph D, Lamb D, Tai KH, Turner S, Matthews J, et al., 'Reasons for initial PSA (iPSA) and biochemical failure (BF) being poor predictors of prostate cancer (PC) mortality', European Journal of Cancer Supplements (ECCO 14 Abstract Book) (2007) [E3]
DOI 10.1016/s1359-6349(07)71071-6
Co-authors Peter Greer, Allison Steigler
2007 Ebert M, Howlett S, Harrison KM, Cornes D, Denham J, Hamilton C, 'Accelerator output in Australasia - Comparison with other international Level 1 studies', Australasian Physical and Engineering Sciences in Medicine (2007) [E3]
2007 Denham J, 'If you do not have a laboratory, then turn your clinic into one!', European Journal of Cancer Supplements (ECCO 14 Abstract Book) (2007) [E3]
DOI 10.1016/s1359-6349(07)70239-2
2007 Ebert M, Harrison K, Cornes D, Howlett S, Denham J, Hamilton C, 'Level I and III dosimetric intercomparison for a prostate 3D-CRT trial', Radiotherapy and Oncology (2007) [E3]
2006 Denham JW, 'CERT vs late response in normal tissues: ambushes or good news?', Radiotherapy and Oncology (2006) [E1]
2006 Greer PB, Dahl K, Ostwald PM, Denham J, Lau P, Hughes C, White M, 'An investigation of MRI dose planning for high precision prostate radiotherapy', Australasian Physical & Engineering Sciences in Medicine (2006) [E3]
Co-authors Peter Greer, Patricia Ostwald
2006 Greer PB, Dahl K, Ostwald PM, Pichler P, Denham J, Wratten C, White M, 'Initial clinical experience with implanted fiducial guided prostate radiotherapy', Australasian Physical & Engineering Sciences in Medicine (2006) [E3]
Co-authors Patricia Ostwald, Peter Greer
2006 Joseph D, Lamb D, Denham J, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variation sand mistaken biochemical failure.', RADIOTHERAPY AND ONCOLOGY (2006)
Co-authors Peter Greer, Allison Steigler
2006 Denham J, Joseph D, Lamb D, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', RADIOTHERAPY AND ONCOLOGY (2006)
Co-authors Peter Greer, Allison Steigler
2006 Haworth A, Joseph D, Lamb D, Duchesne G, Kearvell R, Hooton B, et al., 'Quality control studies for radiation delivery in a multicentre prostate cancer clinical trial', RADIOTHERAPY AND ONCOLOGY (2006)
Co-authors Peter Greer
2006 Denham J, 'CERT vs late response in normal tissues: Ambushes or good news?', Radiotherapy and Oncology (2006) [E3]
2006 Denham J, 'The biological significance of longitudinal changes in PSA level during and after curative treatment for prostate cancer', Radiotherapy and Oncology (2006) [E3]
2006 Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variations and mistaken biochemical failure', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
DOI 10.1016/j.ijrobp.2006.07.632
Co-authors Allison Steigler, Peter Greer
2006 Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA: Post treatment variations and mistaken biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (2006) [E3]
Co-authors Allison Steigler
2006 Denham J, Joseph D, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (2006) [E3]
Co-authors Peter Greer, Allison Steigler
2006 Joseph D, Denham J, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; PSA response signatures (PRS)', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (2006) [E3]
Co-authors Allison Steigler
2006 Denham J, Joseph D, Lamb D, Duchesne G, Copeman M, Lynch K, 'A randomized trial investigating different durations of adjuvant androgen deprivation with and without zoledronic acid in the treatment of localized carcinoma of the prostate', BONE (2006)
DOI 10.1016/j.bone.2006.10.021
2006 Denham JW, 'The biological significance of longitudinal changes in PSA level during and after curative treatment for prostate cancer', - (2006) [E1]
2006 Haworth A, Kearvell R, Price S, Greer PB, Baily M, Hooton B, et al., 'The radar set-up accuracy study', EPI2K6: Programme and Abstracts (2006) [E3]
Co-authors Peter Greer
2005 Ebert MA, Harrison KM, Cornes D, Denham J, Howlett SJ, 'Design and Contruction of a Realistic Pelvic Phantom for a Level III Dosimetry Study', Medical Physics (2005) [E3]
2005 Ebert MA, Howlett SJ, Harrison KM, Cornes D, Denham J, 'On the Road with Elvis - Progress on the National Level III Dosimetry Study', EPSM 2005 Conference Handbook (2005) [E3]
2004 Kacen L, Madjar I, Denham J, Ackland S, Aried S, 'The patient-other dynamics of the decision to forgo or stop active treatment for cancer', Palliative Medicine (2004) [E3]
Co-authors Stephen Ackland
2003 Smithers BM, Burmeister BH, Fitzgerald L, Gebski V, Denham J, Devitt P, et al., 'A randomized controlled trial of surgery alone compared with chemoradiation & surgery: a focus on the surgical outcomes', ANNALS OF SURGICAL ONCOLOGY (2003)
Citations Web of Science - 3
Co-authors Stephen Ackland
2002 Denham J, Lamb D, Joseph D, Mameghan H, Turner S, Franklin I, et al., 'How inconvenient is neo-adjuvant maximal androgen deprivation prior to prostatic irradiation? Results from a large randomised trial', Radiotherapy & Oncology: Journal of the European Society for Therapeutic Radiology and Oncology (2002) [E3]
2002 Wratten C, Hamilton C, O'Brien P, Back M, Kilmurray J, Denham J, 'Changes in breast skin in patients having breast conservation as assessed via high frequency cutaneous ultrasound', Radiotherapy & Oncology: Journal of the European Society for Therapeutic Radiology and Oncology (2002) [E3]
2002 Denham JW, 'How inconvenient is neo-adjuvant maximal androgen deprivation prior to prostatic irradiation? Results from a large randomised trial' (2002) [E1]
2002 Denham JW, 'Quantitative measures of morbidity / organ function' (2002) [E1]
2002 Hood C, Duggan L, Bazley S, Denham J, Budzanowski M, Kron T, 'LiF : Mg,Cu,P 'Pin worms': Miniature detectors for brachytherapy dosimetry', SOLID STATE DOSIMETRY, PTS 1 AND 2, PROCEEDINGS (2002)
2002 Denham J, Lamb D, Ball D, Kovacev O, 'Trans-Tasman Radiation Oncology Group (TROG) Development 1989-2001, and results of trials', British Journal of Cancer (2002) [E3]
2001 Wratten C, O'Brien P, Hamilton C, Back B, Kilmurray J, Wright S, et al., 'Fatigue during breast irradiation and its relationship to plasma cytokines', Proceedings in Radiotherapy and Oncology (2001) [E3]
2001 Denham J, 'Consequential vs generic late effects', Radiotherapy and Oncology (2001) [E4]
2001 Denham J, 'A randomised trial of accelerated and conventional radiotherapy for stafe III and IV squamous cell carcinoma of the head and neck: TROG 91:01', Radiotherapy and Oncology (2001) [E4]
2001 Denham J, 'TROG - goals for the second decade', Radiotherapy and Oncology (2001) [E4]
2001 Denham J, 'Acute Toxicity, not Rectal Sucralfate, Predicts for Late Proctitis - results of a randomised double-blind trail from the Tran-Tasman Radiation Oncology Group', Radiotherapy and Oncology (2001) [E4]
2001 O'Brien P, Franklin C, Poulsen M, Joseph D, Spry N, Denham J, 'Acute toxicity, not rectal sucralfate, predicts for late proctitis - Results of a randomised double-blined trial from the Trans-Tasman Radiation Oncology Group (TROG)', Proceedings of the 43rd Annual ASTRO Meeting in the Internatinal Journal of Radiation Oncology Biology Physics 51(3)suppl 1. (2001) [E3]
2001 Denham JW, 'Upper gastro-intestinal tumours - challenges for the new century' (2001) [E1]
2000 Denham J, 'Epithelial radiation injury: the need to consider an organised tissue response', Radiotherapy and Oncology (2000) [E3]
2000 Hamilton C, Kron T, Wratten C, Denham J, 'Measurement and Correction of Individual Patient Set-Up in Radiotherapy. A Comparison of Two Models', International Journal of Radiation Oncology Biology Physics (2000) [E3]
2000 Denham JW, 'Epithelial radiation injury: the need to consider an organised tissue response' (2000) [E1]
2000 Denham JW, 'The TROG 91.01 randomised controlled trial addressing the question of accelerated fractionation.' (2000) [E1]
2000 Kron T, Hamilton C, Hood C, Wratten C, Denham J, 'Computer assisted decision making after portal imaging', USE OF COMPUTERS IN RADIATION THERAPY (2000)
Show 58 more conferences
Edit

Grants and Funding

Summary

Number of grants 61
Total funding $27,230,846

Click on a grant title below to expand the full details for that specific grant.


20161 grants / $376,612

The role of adjuvant zoledronic acid in locally advanced prostate cancer$376,612

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Jim Denham, Professor David Joseph, Professor G Duchesne, Professor John Attia
Scheme Project Grant
Role Lead
Funding Start 2016
Funding Finish 2017
GNo G1500121
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20152 grants / $247,664

A Humanised in vivo Model to Test Novel Therapeutic Strategies Against Prostate Cancer Bone Metastasis$223,664

Funding body: Worldwide Cancer Research (formerly AICR)

Funding body Worldwide Cancer Research (formerly AICR)
Project Team
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo
Type Of Funding International - Competitive
Category 3IFA
UON N

Radiotherapy treatment for prostate cancer - a change in practice based on direct evidence for targeting and toxicity effects using real outcomes data$24,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Associate Professor Martin Ebert, Dr Jason Dowling, Conjoint Professor Jim Denham, Professor David Joseph, Dr Sarah Gulliford, Professor David Dearnaley, Associate Professor Annette Haworth, Dr Lois Holloway, Professor Tomas Kron, Conjoint Professor Peter Greer
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2017
GNo G1401429
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20131 grants / $15,000

Development of a protocol to test the effectiveness of two drug therapies in the control of prostate cancer$15,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Jim Denham
Scheme Project Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300830
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20122 grants / $1,763,541

Salary & Infrastructure Support 2012 TROG 03.04 RADAR Trial$1,598,541

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team Conjoint Professor Jim Denham
Scheme Project Grant
Role Lead
Funding Start 2012
Funding Finish 2017
GNo G1200438
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Support for Prostate Cancer Trials Group for 2012$165,000

Funding body: Prostate Cancer Awareness & Treatment Group Inc

Funding body Prostate Cancer Awareness & Treatment Group Inc
Project Team Conjoint Professor Jim Denham
Scheme Research Project
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200647
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20114 grants / $1,056,358

Priority Research Centre for Cancer$555,811

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Professor John Forbes, Emeritus Professor Leonie Ashman, Doctor Nikola Bowden, Conjoint Professor Jim Denham, Professor Hubert Hondermarck, Doctor Lisa Lincz, Doctor Jennette Sakoff, Associate Professor Peter Stanwell, Doctor Rick Thorne, Doctor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2016
GNo G1101013
Type Of Funding Internal
Category INTE
UON Y

Does the initial treatment plan predict doses delivered to normal tissues during prostate radiation therapy$349,794

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Conjoint Professor Peter Greer, Dr Jason Dowling, Conjoint Professor Jim Denham, Dr Olivier Salvado
Scheme Research Program
Role Investigator
Funding Start 2011
Funding Finish 2016
GNo G1000377
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Assessment of rectal and urinary toxicity from the RADAR prostate radiotherapy trial – dosimetric constraints for novel symptom clustering, derivation of radiobiological parameters and assessment of$100,753

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Pablo Moscato, Associate Professor Martin Ebert, Conjoint Professor Jim Denham, Professor David Joseph, Associate Professor Kerwyn Foo, Associate Professor Annette Haworth
Scheme Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1100992
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

DVCR Special Grant 2011 $50,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Jim Denham
Scheme Special Project Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1101092
Type Of Funding Internal
Category INTE
UON Y

20103 grants / $779,359

Real-time dose monitoring for patient safety in radiation therapy$360,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Conjoint Professor Peter Greer, Dr Boyd McCurdy, Dr Zdenka Kuncic, Professor Clive Baldock, Conjoint Professor Jim Denham
Scheme Research Grant
Role Investigator
Funding Start 2010
Funding Finish 2012
GNo G0190320
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

RADAR TLX XR Project$320,000

Funding body: Novartis Pharmaceuticals Australia Pty Limited

Funding body Novartis Pharmaceuticals Australia Pty Limited
Project Team
Scheme Project Grant
Role Lead
Funding Start 2010
Funding Finish 2011
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

The evaluation of altered metabolism associated with the development of significant fatigue in prostate cancer patients receiving radiotherapy$99,359

Funding body: The Mason Foundation

Funding body The Mason Foundation
Project Team Professor Hugh Dunstan, Conjoint Professor Jim Denham, Doctor Chris Wratten, Doctor Colin Tang, Doctor Anne Capp, Doctor Tim Roberts, Doctor Diane Sparkes, Doctor Margaret MacDonald
Scheme Medical and Scientific Research Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000674
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

20094 grants / $1,796,215

Enhanced development of generic digital tools for support of clinical trials and education in radiotherapy$585,750

Funding body: Cancer Australia

Funding body Cancer Australia
Project Team
Scheme Priority-driven Collaborative Cancer Research Scheme
Role Investigator
Funding Start 2009
Funding Finish 2011
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Population-based exercise intervention for prostate cancer patients - RADAR$476,024

Funding body: Prostate Cancer Foundation of Australia

Funding body Prostate Cancer Foundation of Australia
Project Team
Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2012
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Investigation of a new electronic portal imaging device for radiation therapy dose delivery$393,441

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Greer, Professor Clive Baldock, Dr Zdenka Kuncic, Conjoint Professor Jim Denham
Scheme Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2011
GNo G0188893
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Tetraspanin proteins in prostate cancer progression and prognosis$341,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Emeritus Professor Leonie Ashman, Doctor Nikki Verrills, Conjoint Professor Jim Denham
Scheme Research Grant
Role Investigator
Funding Start 2009
Funding Finish 2011
GNo G0188877
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20082 grants / $1,054,486

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
Scheme NSW MRSP Infrastructure Grant
Role Investigator
Funding Start 2008
Funding Finish 2009
GNo G0188622
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Improving the verification of intensity modulated radiation therapy with flat-pane imagers$23,196

Funding body: Calvary Mater Newcastle Hospital

Funding body Calvary Mater Newcastle Hospital
Project Team
Scheme Radiation Oncology research fund
Role Lead
Funding Start 2008
Funding Finish 2008
GNo
Type Of Funding Internal
Category INTE
UON N

20077 grants / $3,397,451

Value of androgen deprivation and bisphosphonate therapy in patients treated by radiotherapy for limited prostate cancer$2,403,440

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Jim Denham, Professor David Joseph, Professor G Duchesne, Mrs JEAN Ball
Scheme Project Grant
Role Lead
Funding Start 2007
Funding Finish 2011
GNo G0186391
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Optimal duration of neoadjuvant androgen deprivation therapy in localised prostate cancer$399,565

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Jim Denham, Mrs Allison Steigler
Scheme Project Grant
Role Lead
Funding Start 2007
Funding Finish 2011
GNo G0186389
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

High precision MRI based prostate radiotherapy$301,750

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Conjoint Professor Peter Greer, Conjoint Professor Jim Denham, Dr Sebastien Ourselin, Dr Martin Ebert, Doctor Trish Ostwald, Dr Peter Lau
Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2009
GNo G0186637
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Improving the Verification of Intensity Modulated Radiation Therapy Dose Delivery with Flat-Panel Imagers$139,500

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Conjoint Professor Peter Greer, Dr Martin Ebert, Mr Patrick Cadman, Professor Clive Baldock, Conjoint Professor Jim Denham
Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2008
GNo G0186639
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

The evaluation of altered metabolism in patients who develop chronic fatigue following cancer radiotherapy (ongoing study)$120,000

Funding body: The Mason Foundation

Funding body The Mason Foundation
Project Team Doctor Diane Sparkes, Professor Hugh Dunstan, Doctor Tim Roberts, Associate Professor Surinder Baines, Doctor Chris Wratten, Conjoint Professor Jim Denham, Doctor Margaret MacDonald
Scheme Project Grant
Role Investigator
Funding Start 2007
Funding Finish 2008
GNo G0188042
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

Improving the verification of intensity modulated radiation therapy with flat panel imagers$23,196

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team Conjoint Professor Peter Greer, Professor Clive Baldock, Conjoint Professor Jim Denham
Scheme Project Grant
Role Investigator
Funding Start 2007
Funding Finish 2008
GNo G0188380
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

NHMRC funded Prostate Cancer Trials$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Jim Denham
Scheme Sparke Helmore/NBN Television Corporate Triathlon Award for Research Excellence
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187383
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

20066 grants / $3,684,251

Value of androgen deprivation and bisphosphonate in patients treated by radiotherapy for localised prostate cancer$2,403,438

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2010
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Optimal duration of neoadjuvant androgen deprivation therapy in localised prostate cancer treated by radiotherapy$399,563

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2010
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

The "Be Prepared" Sub-Study of the RADAR Trial$350,000

Funding body: Novartis Pharmaceuticals Australia Pty Limited

Funding body Novartis Pharmaceuticals Australia Pty Limited
Project Team
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2008
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

High precision MRI based prostate radiotherapy$301,750

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team
Scheme Project Grant
Role Investigator
Funding Start 2006
Funding Finish 2008
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

In-vivo verification of radiotherapy dose delivery with a flat-panel imager$139,500

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team
Scheme Project Grant
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

RADAR / 96.01 - Strengthening cancer care grant for clinical trials$90,000

Funding body: Trans-Tasman Radiation Oncology Group

Funding body Trans-Tasman Radiation Oncology Group
Project Team
Scheme Project grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Internal
Category INTE
UON N

20054 grants / $2,436,000

Trans Tasman Radiation Oncology Group (TROG)$1,765,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Dr David Ball, Conjoint Associate Professor Peter O'Brien, Assoc. Prof Bryan Burmeister, Professor G Duchesne, Professor David Joseph, Conjoint Professor Jim Denham
Scheme Enabling Grants - Clinical Trials Resources
Role Investigator
Funding Start 2005
Funding Finish 2011
GNo G0184605
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

The timing of androgen deprivation in relapsed or non-curable prostate cancer patients$621,000

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team
Scheme Project Grant
Role Lead
Funding Start 2005
Funding Finish 2007
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

The evaluation of altered metabolism in chronic fatigue patients following cancer radiotherapy and the efficacy of amino acid supplementation$35,000

Funding body: The Mason Foundation

Funding body The Mason Foundation
Project Team Professor Hugh Dunstan, Doctor Tim Roberts, Conjoint Professor Jim Denham, Doctor Chris Wratten, Associate Professor Surinder Baines
Scheme Project Grant
Role Investigator
Funding Start 2005
Funding Finish 2005
GNo G0185518
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

2005 RIBG allocation$15,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Jim Denham
Scheme Research Infrastructure Block Grant (RIBG)
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0185794
Type Of Funding Internal
Category INTE
UON Y

20043 grants / $5,866,375

The RADAR Trial$4,100,000

Funding body: Abbott Australasia Pty Ltd

Funding body Abbott Australasia Pty Ltd
Project Team
Scheme Research Grant
Role Lead
Funding Start 2004
Funding Finish 2008
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

Value and androgen deprivation and bisphosphonate therapy in patients treated by radiotherapy for limited prostate cancer.$1,757,375

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Jim Denham, Professor David Joseph, Professor G Duchesne
Scheme Project Grant
Role Lead
Funding Start 2004
Funding Finish 2006
GNo G0182877
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Deciding to forgo or stop active treatment for cancer$9,000

Funding body: Newcastle Mater Misericordiae Hospital

Funding body Newcastle Mater Misericordiae Hospital
Project Team
Scheme Margaret Mitchell Research Grant Scheme
Role Lead
Funding Start 2004
Funding Finish 2004
GNo
Type Of Funding Internal
Category INTE
UON N

20034 grants / $1,876,514

The RADAR Trial$1,800,000

Funding body: Novartis Pharmaceuticals Australia Pty Limited

Funding body Novartis Pharmaceuticals Australia Pty Limited
Project Team
Scheme Project Grant
Role Lead
Funding Start 2003
Funding Finish 2007
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

Interdisciplinary research assistant: radiotherapy / radiology / physics$37,014

Funding body: The University of Newcastle

Funding body The University of Newcastle
Project Team
Scheme Research infrastructure block grant
Role Lead
Funding Start 2003
Funding Finish 2003
GNo
Type Of Funding Internal
Category INTE
UON N

RADAR - Randomised androgen deprivation and radiotherapy - in prostate cancer.$30,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Jim Denham, Ms Olga Kovacev
Scheme Research Grant
Role Lead
Funding Start 2003
Funding Finish 2005
GNo G0182629
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Determinants of Radiation-induced fatigue in breast cancer patients$9,500

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Jim Denham, Doctor Chris Wratten, Professor Hugh Dunstan, Doctor Tim Roberts
Scheme Project Grant
Role Lead
Funding Start 2003
Funding Finish 2003
GNo G0182343
Type Of Funding Internal
Category INTE
UON Y

20021 grants / $275,000

Optimal duration of neoadjuvant androgen deprivation therapy in localised prostate cancer$275,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Jim Denham, Ms J Francis
Scheme Project Grant
Role Lead
Funding Start 2002
Funding Finish 2006
GNo G0180880
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20011 grants / $96,000

CCCR Clerical infrastructure support$96,000

Funding body: Hunter Medical Research Institute (HMRI)

Funding body Hunter Medical Research Institute (HMRI)
Project Team
Scheme Project Grant
Role Lead
Funding Start 2001
Funding Finish 2003
GNo
Type Of Funding Internal
Category INTE
UON N

20002 grants / $30,000

Optimising breast cancer therapy.$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Trish Ostwald, Conjoint Associate Professor Chris Hamilton, Dr Tomas Kron, Conjoint Professor Jim Denham
Scheme Research Grant
Role Investigator
Funding Start 2000
Funding Finish 2000
GNo G0180201
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Pre-treatment Uracil, Dihydrouracil ratio as a predictor of 5FU pharmacokinetics and myelotoxicity of chemotherapy$10,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team
Scheme ARC Small Grant / RMC Project grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo
Type Of Funding Internal
Category INTE
UON N

19995 grants / $882,466

A randomised trial investigating the effectiveness of different durations of maximal androgen deprivation prior to and during definitive radiation therapy for locally advanced carcinoma of the prostate$489,225

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team
Scheme Project Grant
Role Investigator
Funding Start 1999
Funding Finish 2006
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Optimal duration of neoadjuvant androgen deprivation therapy in localised prostate cancer$217,868

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Jim Denham, Keith Dear
Scheme Project Grant
Role Lead
Funding Start 1999
Funding Finish 2001
GNo G0178347
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Development of a dose verification system for patients undergoing brachytherapy$123,285

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Dr Tomas Kron, Conjoint Professor Jim Denham, Ms L Duggan, Professor Anatoly Rozenfeld
Scheme Project Grant
Role Investigator
Funding Start 1999
Funding Finish 2000
GNo G0178360
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Clerical support for the Trans-Tasman Radiation Oncology Group's coordinating infrastructure$36,811

Funding body: The University of Newcastle

Funding body The University of Newcastle
Project Team
Scheme Support funding
Role Lead
Funding Start 1999
Funding Finish 1999
GNo
Type Of Funding Internal
Category INTE
UON N

Temporary Infrastructural clerical support for the Trans-Tasman Radiation Oncology Group (TROG)$15,277

Funding body: Royal Australian and New Zealand College of Radiologists

Funding body Royal Australian and New Zealand College of Radiologists
Project Team
Scheme Project grant
Role Lead
Funding Start 1999
Funding Finish 1999
GNo
Type Of Funding Internal
Category INTE
UON N

19981 grants / $122,417

Dose verification for patients undergoing brachytherapy$122,417

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Dr Tomas Kron, Ms L Duggan, Professor Anatoly Rozenfeld, Conjoint Professor Jim Denham
Scheme Project Grant
Role Investigator
Funding Start 1998
Funding Finish 1999
GNo G0177177
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

19971 grants / $226,326

A randomised controlled trial in oesophageal cancer comparing surgery alone with chemoradiation and surgery$226,326

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team
Scheme Project Grant
Role Lead
Funding Start 1997
Funding Finish 1999
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

19962 grants / $1,100,000

The 96.01 Trial$600,000

Funding body: Schering-Plough

Funding body Schering-Plough
Project Team
Scheme Discovery project
Role Lead
Funding Start 1996
Funding Finish 1999
GNo
Type Of Funding Not Known
Category UNKN
UON N

The 96.01 Trial$500,000

Funding body: Astra Zeneca

Funding body Astra Zeneca
Project Team
Scheme Discovery project
Role Lead
Funding Start 1996
Funding Finish 1999
GNo
Type Of Funding Not Known
Category UNKN
UON N

19931 grants / $9,595

A problem based approach to multidisciplinary cancer management through the use of small format interactive disc as a teaching medium$9,595

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Jim Denham
Scheme Teaching Committee Teaching Grants
Role Lead
Funding Start 1993
Funding Finish 1993
GNo G0175912
Type Of Funding Internal
Category INTE
UON Y

19911 grants / $70,944

Low dose rate telepathy: normal tissue effects$70,944

Funding body: National Health & Medical Research Council

Funding body National Health & Medical Research Council
Project Team
Scheme Discovery project
Role Lead
Funding Start 1991
Funding Finish 1992
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

19902 grants / $58,272

Cost and safety aspect of high energy electrons$43,272

Funding body: Department of Community Services and health

Funding body Department of Community Services and health
Project Team
Scheme Discovery project
Role Investigator
Funding Start 1990
Funding Finish 1990
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Evaluation of low dose rate telepathy in locally advanced head and neck cancer$15,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team
Scheme Project Grant
Role Lead
Funding Start 1990
Funding Finish 1990
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

19881 grants / $10,000

Low dose rate telepathy - technical aspects$10,000

Funding body: Hunter Valley Cancer Appeal

Funding body Hunter Valley Cancer Appeal
Project Team
Scheme Discovery project
Role Lead
Funding Start 1988
Funding Finish 1988
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Research Supervision

Number of supervisions

Completed4
Current1

Total current UON EFTSL

PhD0.3

Current Supervision

Commenced Level of Study Research Title / Program / Supervisor Type
2014 PhD Localised Advanced Prostate Cancer (LAPC) Survivors and Their Partners: Investigation of Their Survivorship and Unmet Needs Post Cancer Active Treatment
PhD (CommunityMed & ClinEpid), Faculty of Health and Medicine, The University of Newcastle
Principal Supervisor

Past Supervision

Year Level of Study Research Title / Program / Supervisor Type
2006 PhD Remote X-Ray Operator Radiography: a Case Study in Interprofessional Rural Clinical Practice
Medical Science, The University of Newcastle
Co-Supervisor
2004 Masters Development and Critical Evaluation of an Independent Verification System for Monitor Unit Calculations in Photon Radiotherapy
Physics, The University of Newcastle
Co-Supervisor
1998 PhD Determination of the Dose Distribution of Therapeutic Electrons at Interfaces
Physics, University of Newcastle
Co-Supervisor
1998 Masters Reflectance Spectrophotometry in the Assessment of Radiation Erythema
Medical Science, University of Tasmania
Co-Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 218
New Zealand 59
United Kingdom 32
United States 17
Canada 8
More...
Edit

News

NHMRC

NHMRC funding success 2016

November 13, 2015

Conjoint Professor Jim Denham has been awarded more than $376,000 in NHMRC Project Grant funding commencing in 2016 for his research project The role of adjuvant zoledronic acid in locally advanced prostate cancer.

Prostate cancer breakthrough widget

Prostate cancer breakthrough

August 15, 2014

University of Newcastle researchers are leaders of a trials group that has discovered a powerful new prostate cancer treatment regime that can reduce the spread of aggressive but apparently localised tumours by more than 40 per cent.

HMRI logo

Highest Hunter honour for leading prostate cancer researcher

March 15, 2013

A pioneering prostate cancer researcher will today be recognised for his untiring work in early intervention campaigns and his groundbreaking research into better treatments for those threatened by locally advanced cancers.

Conjoint Professor Jim Denham

Position

Conjoint Professor
Prostate Cancer Trials Group
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email jim.denham@newcastle.edu.au
Phone (02) 4985 4018
Fax (02) 4968 4924

Office

Room WTPO117
Building Waratah Post Office
Location Other

,
Edit